Blockade	O
of	O
T-cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
.	O

Dithiocarbamates	O
(	O
DTCs	O
)	O
have	O
recently	O
been	O
reported	O
as	O
powerful	O
inhibitors	O
of	O
NF-kappaB	B-protein
activation	O
in	O
a	O
number	O
of	O
cell	O
types	O
.	O

Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF-kappaB	B-protein
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	B-protein
which	O
are	O
induced	O
during	O
T-cell	O
activation	O
.	O

This	O
inhibition	O
,	O
which	O
occurred	O
with	O
a	O
parallel	O
activation	O
of	O
c-Jun	B-protein
transactivating	O
functions	O
and	O
expression	O
,	O
was	O
reflected	O
by	O
transfection	O
experiments	O
at	O
the	O
IL-2	B-DNA
promoter	I-DNA
level	O
,	O
and	O
involved	O
not	O
only	O
the	O
inhibition	O
of	O
NF-kappaB	B-protein
-driven	O
reporter	O
activation	O
but	O
also	O
that	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

Accordingly	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
pyrrolidine	O
DTC	O
(	O
PDTC	O
)	O
prevented	O
NF-kappaB	B-protein
,	O
and	O
NFAT	B-protein
DNA-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
with	O
either	O
phorbol	O
myristate	O
acetate	O
plus	O
ionophore	O
or	O
antibodies	O
against	O
the	O
CD3-T-cell	B-protein
receptor	I-protein
complex	I-protein
and	O
simultaneously	O
activated	O
the	O
binding	O
of	O
AP-1	B-protein
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B-protein
and	I-protein
NFATc	I-protein
family	I-protein
members	I-protein
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	B-protein
and	O
mRNA	O
induction	O
of	O
NFATc	B-protein
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	B-protein
and	O
NFATc	B-protein
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	B-protein
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	B-protein
factor	I-protein
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c-Jun	B-protein
NH2-terminal	I-protein
kinase	I-protein
(	O
JNK	B-protein
)	O
can	O
act	O
by	O
directly	O
phosphorylating	O
NFATp	B-protein
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	B-protein
and	O
NF-KB	B-protein
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

MOLECULAR	NULL
AND	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
Nov.	NULL
1997	NULL
,	NULL
p.	NULL
6437-6447	NULL
0270-7306/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

17	NULL
,	NULL
No	NULL
.	NULL

11	NULL
Blockade	NULL
of	NULL
T-Cell	NULL
Activation	NULL
by	NULL
Dithiocarbamates	NULL
Involves	NULL
Novel	NULL
Mechanisms	NULL
of	NULL
Inhibition	NULL
of	NULL
Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T	NULL
Cells	NULL
SARA	NULL
MARTiNEZ-MARTiNEZ,1	NULL
PABLO	NULL
GOMEZ	NULL
net	NULL
ARCO	NULL
,	NULL
``	NULL
ANGEL	NULL
LUIS	NULL
ARMESILLA	NULL
,	NULL
!	NULL

JOSE	NULL
ARAMBURU	NULL
,	NULL
``	NULL
CHUN	NULL
LUO	NULL
,	NULL
``	NULL
ANJANA	NULL
RAO	NULL
,	NULL
``	NULL
anp	NULL
JUAN	NULL
MIGUEL	NULL
REDONDO	NULL
!	NULL

*	NULL
Servicio	NULL
de	NULL
Inmunologia	NULL
,	NULL
Hospital	NULL
de	NULL
la	NULL
Princesa	NULL
y	NULL
Centro	NULL
de	NULL
Biologia	NULL
Molecular	NULL
,	NULL
Consejo	NULL
Superior	NULL
de	NULL
Investigaciones	NULL
Cientificas	NULL
(	NULL
CSIC	NULL
)	NULL
-Universidad	NULL
Autonoma	NULL
de	NULL
Madrid	NULL
(	NULL
UAM	NULL
)	NULL
,	NULL
Madrid	NULL
28049	NULL
,	NULL
Spain	NULL
,	NULL
``	NULL
and	NULL
Center	NULL
for	NULL
Blood	NULL
Research	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
021152	NULL
Received	NULL
13	NULL
March	NULL
1997/Returned	NULL
for	NULL
modification	NULL
9	NULL
May	NULL
1997/Accepted	NULL
6	NULL
August	NULL
1997	NULL
Dithiocarbamates	NULL
(	NULL
DTCs	NULL
)	NULL
have	NULL
recently	NULL
been	NULL
reported	NULL
as	NULL
powerful	NULL
inhibitors	NULL
of	NULL
NF-B	NULL
activation	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

Given	NULL
the	NULL
role	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
inflammatory	NULL
response	NULL
,	NULL
NF-KB	NULL
inhibitors	NULL
have	NULL
been	NULL
suggested	NULL
as	NULL
potential	NULL
therapeutic	NULL
drugs	NULL
for	NULL
inflammatory	NULL
diseases	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
DTCs	NULL
inhibited	NULL
both	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
synthesis	NULL
and	NULL
membrane	NULL
expression	NULL
of	NULL
antigens	NULL
which	NULL
are	NULL
induced	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

This	NULL
inhibition	NULL
,	NULL
which	NULL
occurred	NULL
with	NULL
a	NULL
parallel	NULL
activation	NULL
of	NULL
c-Jun	NULL
transactivating	NULL
functions	NULL
and	NULL
expression	NULL
,	NULL
was	NULL
reflected	NULL
by	NULL
transfection	NULL
experiments	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
level	NULL
,	NULL
and	NULL
involved	NULL
not	NULL
only	NULL
the	NULL
inhibition	NULL
of	NULL
NF-B-driven	NULL
reporter	NULL
activation	NULL
but	NULL
also	NULL
that	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
indicated	NULL
that	NULL
pyrrolidine	NULL
DTC	NULL
(	NULL
PDTC	NULL
)	NULL
prevented	NULL
NF-KB	NULL
,	NULL
and	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
either	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
plus	NULL
ionophore	NULL
or	NULL
antibodies	NULL
against	NULL
the	NULL
CD3-T-cell	NULL
receptor	NULL
complex	NULL
and	NULL
simultaneously	NULL
activated	NULL
the	NULL
binding	NULL
of	NULL
AP-1	NULL
.	NULL

Furthermore	NULL
,	NULL
PDTC	NULL
differentially	NULL
targeted	NULL
both	NULL
NFAT	NULL
p	NULL
and	NULL
NFATc	NULL
family	NULL
members	NULL
,	NULL
inhibiting	NULL
the	NULL
transactivation	NULL
functions	NULL
of	NULL
NFATp	NULL
and	NULL
mRNA	NULL
induction	NULL
of	NULL
NFATc	NULL
.	NULL

Strikingly	NULL
,	NULL
Western	NULL
blotting	NULL
and	NULL
immunocytochemical	NULL
experiments	NULL
indicated	NULL
that	NULL
PDTC	NULL
promoted	NULL
a	NULL
transient	NULL
and	NULL
rapid	NULL
shuttling	NULL
of	NULL
NFATp	NULL
and	NULL
NFATe	NULL
,	NULL
leading	NULL
to	NULL
their	NULL
accelerated	NULL
export	NULL
from	NULL
the	NULL
nucleus	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
an	NULL
NFAT	NULL
kinase	NULL
by	NULL
PDTC	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
rapid	NULL
shuttling	NULL
of	NULL
the	NULL
NFAT	NULL
,	NULL
therefore	NULL
transiently	NULL
converting	NULL
the	NULL
sustained	NULL
transactivation	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
that	NULL
occurs	NULL
during	NULL
lymphocyte	NULL
activation	NULL
,	NULL
and	NULL
show	NULL
that	NULL
c-Jun	NULL
NH-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
can	NULL
act	NULL
by	NULL
directly	NULL
phosphorylating	NULL
NFATp	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
combined	NULL
inhibitory	NULL
effects	NULL
on	NULL
NFAT	NULL
and	NULL
NF-KB	NULL
support	NULL
a	NULL
potential	NULL
use	NULL
of	NULL
DTCs	NULL
as	NULL
immunosuppressants	NULL
.	NULL

The	NULL
interaction	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
antigens	NULL
triggers	NULL
a	NULL
complex	NULL
signaling	NULL
cascade	NULL
that	NULL
switches	NULL
on	NULL
the	NULL
gene	NULL
program	NULL
leading	NULL
to	NULL
T-cell	NULL
activation	NULL
.	NULL

During	NULL
this	NULL
process	NULL
,	NULL
T	NULL
cells	NULL
express	NULL
the	NULL
autocrine	NULL
growth	NULL
factor	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
which	NULL
promotes	NULL
cell	NULL
proliferation	NULL
by	NULL
interacting	NULL
with	NULL
its	NULL
receptor	NULL
,	NULL
also	NULL
expressed	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
has	NULL
been	NULL
extensively	NULL
analyzed	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
a	NULL
275-bp	NULL
region	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

Cis-Acting	NULL
elements	NULL
for	NULL
several	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
identified	NULL
within	NULL
this	NULL
regulatory	NULL
region	NULL
.	NULL

The	NULL
factors	NULL
which	NULL
bind	NULL
to	NULL
these	NULL
motifs	NULL
include	NULL
AP-1	NULL
,	NULL
NF-kB	NULL
,	NULL
Oct-1	NULL
,	NULL
and	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
family	NULL
proteins	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
15	NULL
and	NULL
26	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
NFAT	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Binding	NULL
sites	NULL
for	NULL
NFAT	NULL
have	NULL
also	NULL
been	NULL
found	NULL
within	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
several	NULL
cytokines	NULL
,	NULL
including	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-5	NULL
(	NULL
10-12	NULL
,	NULL
17	NULL
,	NULL
27	NULL
,	NULL
34	NULL
,	NULL
44	NULL
,	NULL
64	NULL
)	NULL
.	NULL

NFAT	NULL
is	NULL
composed	NULL
of	NULL
a	NULL
complex	NULL
whose	NULL
binding	NULL
specificity	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
cytosolic	NULL
subunit	NULL
and	NULL
an	NULL
inducible	NULL
nuclear	NULL
component	NULL
comprised	NULL
of	NULL
AP-1	NULL
family	NULL
members	NULL
.	NULL

The	NULL
cytoplasmic	NULL
subunit	NULL
is	NULL
encoded	NULL
by	NULL
a	NULL
family	NULL
of	NULL
genes	NULL
constituted	NULL
by	NULL
at	NULL
least	NULL
four	NULL
structurally	NULL
related	NULL
NFAT	NULL
members	NULL
,	NULL
NFATp/	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Centro	NULL
de	NULL
Biologia	NULL
Molecular	NULL
Severo	NULL
Ochoa	NULL
(	NULL
CBM-SQ	NULL
)	NULL
,	NULL
Facultad	NULL
de	NULL
Ciencias	NULL
,	NULL
Universidad	NULL
Autonoma	NULL
de	NULL
Madrid	NULL
,	NULL
Cantoblanco	NULL
,	NULL
28049	NULL
Madrid	NULL
,	NULL
Spain	NULL
.	NULL

Phone	NULL
:	NULL
34-1-397	NULL
84	NULL
13	NULL
.	NULL

Fax	NULL
:	NULL
34-1-397	NULL
47	NULL
99	NULL
.	NULL

6437	NULL
NFAT1	NULL
,	NULL
NFATc	NULL
,	NULL
NFAT3	NULL
,	NULL
and	NULL
NFATX/NFAT4/NFATc3	NULL
(	NULL
20	NULL
,	NULL
23	NULL
,	NULL
31	NULL
,	NULL
35	NULL
,	NULL
37	NULL
,	NULL
43	NULL
)	NULL
.	NULL

These	NULL
members	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
upon	NULL
calcium	NULL
mobilization	NULL
during	NULL
T-cell	NULL
activation	NULL
involving	NULL
the	NULL
calcineurin-dependent	NULL
dephosphorylation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
.	NULL

Blockade	NULL
of	NULL
this	NULL
pathway	NULL
by	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK	NULL
506	NULL
results	NULL
in	NULL
inhibition	NULL
of	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
,	NULL
thus	NULL
preventing	NULL
the	NULL
subsequent	NULL
dephosphorylation	NULL
and	NULL
translocation	NULL
of	NULL
NFAT	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Hence	NULL
,	NULL
NFAT	NULL
can	NULL
be	NULL
considered	NULL
a	NULL
secondary	NULL
target	NULL
of	NULL
the	NULL
action	NULL
of	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
,	NULL
whose	NULL
inhibition	NULL
accounts	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
for	NULL
the	NULL
transcriptional	NULL
inhibitory	NULL
effects	NULL
of	NULL
the	NULL
immunosuppressants	NULL
(	NULL
28	NULL
,	NULL
55	NULL
)	NULL
.	NULL

In	NULL
the	NULL
nucleus	NULL
,	NULL
NFAT	NULL
family	NULL
proteins	NULL
can	NULL
interact	NULL
with	NULL
the	NULL
inducible	NULL
nuclear	NULL
component	NULL
formed	NULL
by	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
members	NULL
to	NULL
bind	NULL
cooperatively	NULL
and	NULL
transactivate	NULL
NFAT	NULL
sites	NULL
in	NULL
vitro	NULL
(	NULL
8	NULL
,	NULL
15	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Dithiocarbamates	NULL
(	NULL
DTCs	NULL
)	NULL
are	NULL
antioxidant	NULL
compounds	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
exert	NULL
opposite	NULL
effects	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
NF-kB	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
DTCs	NULL
inhibit	NULL
activation	NULL
of	NULL
NF-kB	NULL
by	NULL
a	NULL
number	NULL
of	NULL
stimuli	NULL
that	NULL
promote	NULL
the	NULL
production	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
proposed	NULL
as	NULL
common	NULL
second	NULL
messengers	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
(	NULL
3	NULL
,	NULL
52	NULL
,	NULL
57	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
AP-1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
DTCs	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
T	NULL
lymphocytes	NULL
(	NULL
18	NULL
,	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
primary	NULL
cellular	NULL
targets	NULL
involved	NULL
in	NULL
DTC-mediated	NULL
changes	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
have	NULL
not	NULL
been	NULL
identified	NULL
so	NULL
far	NULL
,	NULL
the	NULL
inhibition	NULL
by	NULL
pyrrolidine	NULL
DTC	NULL
(	NULL
PDTC	NULL
)	NULL
of	NULL
NF-KB	NULL
involves	NULL
the	NULL
6438	NULL
MARTINEZ-MARTINEZ	NULL
ET	NULL
AL	NULL
.	NULL

blockade	NULL
of	NULL
IxB-	NULL
Â«	NULL
phosphorylation	NULL
(	NULL
66	NULL
)	NULL
,	NULL
whereas	NULL
PDTC-mediated	NULL
AP-1	NULL
activation	NULL
in	NULL
T	NULL
lymphocytes	NULL
is	NULL
accompanied	NULL
by	NULL
a	NULL
strong	NULL
and	NULL
sustained	NULL
activation	NULL
of	NULL
c-Jun	NULL
NH	NULL
,	NULL
-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Since	NULL
DTCs	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
transcription	NULL
factors	NULL
important	NULL
for	NULL
gene	NULL
regulation	NULL
during	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
,	NULL
we	NULL
analyzed	NULL
here	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
agents	NULL
on	NULL
IL-2	NULL
gene	NULL
expression	NULL
and	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
its	NULL
promoter	NULL
region	NULL
,	NULL
which	NULL
is	NULL
in	NULL
turn	NULL
regulated	NULL
by	NULL
multiple	NULL
transcription	NULL
factors	NULL
that	NULL
integrate	NULL
signals	NULL
transmitted	NULL
from	NULL
different	NULL
pathways	NULL
.	NULL

We	NULL
found	NULL
that	NULL
despite	NULL
the	NULL
activation	NULL
exerted	NULL
on	NULL
AP-1	NULL
,	NULL
DTCs	NULL
inhibited	NULL
NFAT-dependent	NULL
transactivation	NULL
and	NULL
binding	NULL
by	NULL
mechanisms	NULL
different	NULL
from	NULL
those	NULL
mediated	NULL
by	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
FK	NULL
506	NULL
and	NULL
CsA	NULL
.	NULL

We	NULL
discuss	NULL
the	NULL
potential	NULL
benefits	NULL
derived	NULL
from	NULL
the	NULL
use	NULL
of	NULL
DTCs	NULL
as	NULL
immunosuppressants	NULL
and	NULL
speculate	NULL
on	NULL
the	NULL
putative	NULL
involvement	NULL
of	NULL
an	NULL
NFAT	NULL
kinase	NULL
mediating	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
these	NULL
agents	NULL
on	NULL
the	NULL
NFATp	NULL
transactivation	NULL
functions	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
and	NULL
reagents	NULL
.	NULL

Jurkat	NULL
and	NULL
PEER	NULL
cells	NULL
(	NULL
Â«	NULL
B	NULL
and	NULL
y8	NULL
T-cell	NULL
lines	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco-BRL	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
healthy	NULL
volunteers	NULL
,	NULL
and	NULL
venous	NULL
blood	NULL
was	NULL
drawn	NULL
with	NULL
heparin	NULL
syringes	NULL
and	NULL
diluted	NULL
in	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
saline	NULL
solution	NULL
.	NULL

The	NULL
suspension	NULL
was	NULL
layered	NULL
over	NULL
a	NULL
Ficoll-Hypaque	NULL
cushion	NULL
and	NULL
centrifuged	NULL
.	NULL

Mononuclear	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
at	NULL
37Â°C	NULL
for	NULL
1	NULL
h	NULL
on	NULL
plastic	NULL
dishes	NULL
to	NULL
remove	NULL
monocytes	NULL
.	NULL

The	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBLs	NULL
)	NULL
(	NULL
5	NULL
X	NULL
10Â°	NULL
per	NULL
well	NULL
)	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MAb	NULL
)	NULL
in	NULL
a	NULL
24-well	NULL
tissue	NULL
culture	NULL
plate	NULL
previously	NULL
precoated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
100	NULL
pl	NULL
of	NULL
a	NULL
10-pg/ml	NULL
solution	NULL
of	NULL
UCHT.1	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
9	NULL
)	NULL
at	NULL
37Â°C	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
PDTC	NULL
,	NULL
diethyl	NULL
DTC	NULL
(	NULL
DDTC	NULL
)	NULL
,	NULL
disulfiram	NULL
,	NULL
butylated	NULL
hydroxyan-isole	NULL
(	NULL
BHA	NULL
)	NULL
,	NULL
N-acetylcysteine	NULL
(	NULL
NAC	NULL
)	NULL
,	NULL
and	NULL
the	NULL
calcium	NULL
ionophore	NULL
A23187	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

CsA	NULL
was	NULL
obtained	NULL
from	NULL
Sandoz	NULL
.	NULL

Antibodies	NULL
,	NULL
flow	NULL
cytometry	NULL
analysis	NULL
,	NULL
and	NULL
IL-2	NULL
immunoassay	NULL
.	NULL

After	NULL
different	NULL
treatments	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
resuspended	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
4Â°C	NULL
for	NULL
30	NULL
min	NULL
with	NULL
hybridoma	NULL
culture	NULL
supernatant	NULL
of	NULL
TP1/55	NULL
anti-CD69	NULL
MAb	NULL
(	NULL
50	NULL
)	NULL
or	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
anti-CD25	NULL
antibody	NULL
from	NULL
Becton	NULL
Dickinson	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
300	NULL
pl	NULL
of	NULL
propidium	NULL
iodide	NULL
(	NULL
2	NULL
ng/pl	NULL
)	NULL
,	NULL
and	NULL
bound	NULL
anti-CD69	NULL
antibody	NULL
was	NULL
detected	NULL
with	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
rabbit	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
anti-mouse	NULL
immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
(	NULL
Dako	NULL
A/S	NULL
,	NULL
Roskilde	NULL
,	NULL
Denmark	NULL
)	NULL
.	NULL

The	NULL
supernatant	NULL
from	NULL
the	NULL
myeloma	NULL
P3X63	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

The	NULL
anti-CD3	NULL
MAbs	NULL
were	NULL
purified	NULL
by	NULL
affinity	NULL
chromatography	NULL
on	NULL
a	NULL
protein	NULL
A-Sepha-rose	NULL
column	NULL
.	NULL

When	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
antibodies	NULL
,	NULL
the	NULL
biotinyl-ated	NULL
TP1/55	NULL
MAb	NULL
was	NULL
used	NULL
to	NULL
monitor	NULL
CD69	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
biotinyl-ated	NULL
TEA	NULL
2/1	NULL
(	NULL
anti-ELAM-1	NULL
MAb	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
in	NULL
a	NULL
FACScan	NULL
cytofluorometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Analysis	NULL
was	NULL
performed	NULL
with	NULL
viable	NULL
cells	NULL
(	NULL
typically	NULL
higher	NULL
than	NULL
95	NULL
%	NULL
)	NULL
as	NULL
determined	NULL
by	NULL
staining	NULL
with	NULL
the	NULL
fluorochrome	NULL
propidium	NULL
iodide	NULL
.	NULL

Since	NULL
we	NULL
observed	NULL
variability	NULL
among	NULL
different	NULL
batches	NULL
of	NULL
Jurkat	NULL
cells	NULL
regarding	NULL
the	NULL
doses	NULL
of	NULL
DTCs	NULL
required	NULL
to	NULL
achieve	NULL
maximal	NULL
inhibition	NULL
of	NULL
membrane	NULL
markers	NULL
of	NULL
T-cell	NULL
activation	NULL
,	NULL
we	NULL
routinely	NULL
performed	NULL
flow	NULL
cytometry	NULL
analysis	NULL
of	NULL
CD69	NULL
with	NULL
doses	NULL
of	NULL
PDTC	NULL
ranging	NULL
between	NULL
50	NULL
and	NULL
200	NULL
M	NULL
to	NULL
select	NULL
the	NULL
minimal	NULL
dose	NULL
of	NULL
PDTC	NULL
that	NULL
achieved	NULL
the	NULL
maximal	NULL
inhibition	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
.	NULL

IL-2	NULL
levels	NULL
were	NULL
measured	NULL
with	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
kit	NULL
purchased	NULL
from	NULL
Amersham	NULL
.	NULL

Cell	NULL
supernatants	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
collected	NULL
20	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

Plasmid	NULL
constructs	NULL
.	NULL

The	NULL
reporter	NULL
constructs	NULL
NFAT-Luc	NULL
,	NULL
containing	NULL
three	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
NFAT	NULL
binding	NULL
site	NULL
fused	NULL
to	NULL
the	NULL
IL-2	NULL
minimal	NULL
promoter	NULL
,	NULL
and	NULL
IL-2-Luc	NULL
,	NULL
containing	NULL
the	NULL
region	NULL
spanning	NULL
from	NULL
-326	NULL
to	NULL
+45	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
or	NULL
enhancer	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
and	NULL
were	NULL
provided	NULL
by	NULL
G.	NULL
Crabtree	NULL
.	NULL

The	NULL
pKBF-Luc	NULL
construct	NULL
includes	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
motif	NULL
of	NULL
the	NULL
H-2KÂ®	NULL
gene	NULL
upstream	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
minimal	NULL
promoter	NULL
driving	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
73	NULL
)	NULL
.	NULL

The	NULL
GAL4	NULL
plasmids	NULL
RSV-GALA4-DBD	NULL
(	NULL
RSV	NULL
is	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
)	NULL
and	NULL
GALA4-hNFAT1	NULL
(	NULL
1-415	NULL
)	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
GAL4-hNFAT1	NULL
(	NULL
1-415	NULL
)	NULL
plasmid	NULL
encodes	NULL
the	NULL
transactivation	NULL
domain	NULL
of	NULL
NFAT1/p	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
415	NULL
)	NULL
in	NULL
frame	NULL
with	NULL
the	NULL
GAL4	NULL
DNA	NULL
binding	NULL
domain	NULL
(	NULL
DBD	NULL
)	NULL
.	NULL

RSV-GALA4-DBD	NULL
is	NULL
the	NULL
parental	NULL
vector	NULL
including	NULL
just	NULL
the	NULL
DBD	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
to	NULL
147	NULL
)	NULL
of	NULL
GALA	NULL
.	NULL

RSV-GAL4-c-Jun	NULL
(	NULL
wild	NULL
type	NULL
)	NULL
and	NULL
RSV-GAL4-c-Jun	NULL
S	NULL
;	NULL
+	NULL
S	NULL
;	NULL
,	NULL
constructs	NULL
that	NULL
encode	NULL
the	NULL
wild-type	NULL
transactivation	NULL
domain	NULL
of	NULL
c-Jun	NULL
and	NULL
this	NULL
domain	NULL
mutated	NULL
in	NULL
its	NULL
phosphorylation	NULL
sites	NULL
(	NULL
Ser	NULL
63	NULL
and	NULL
Ser	NULL
73	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
45	NULL
)	NULL
,	NULL
were	NULL
gifts	NULL
from	NULL
P.	NULL
Angel	NULL
.	NULL

The	NULL
GAL4-Luc	NULL
reporter	NULL
plasmid	NULL
,	NULL
including	NULL
five	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL..	NULL
GAL4	NULL
DNA	NULL
binding	NULL
sites	NULL
fused	NULL
to	NULL
the	NULL
luciferase	NULL
gene	NULL
(	NULL
provided	NULL
by	NULL
R.	NULL
Perona	NULL
)	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Transient	NULL
transfections	NULL
and	NULL
luciferase	NULL
assays	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
Lipofectin	NULL
reagent	NULL
(	NULL
Gibco	NULL
BRL	NULL
)	NULL
for	NULL
8	NULL
h	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
OPTIMEM	NULL
(	NULL
Gibco	NULL
BRL	NULL
)	NULL
or	NULL
were	NULL
cotransfected	NULL
with	NULL
2	NULL
mg	NULL
of	NULL
GAL4	NULL
expression	NULL
plasmids	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
GAL4-Luc	NULL
construct	NULL
,	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
Lipofectin	NULL
reagent	NULL
added	NULL
for	NULL
8	NULL
h	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
OPTIMEM	NULL
in	NULL
transactivation	NULL
experiments	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
diluted	NULL
in	NULL
complete	NULL
medium	NULL
and	NULL
after	NULL
36	NULL
h	NULL
were	NULL
preincubated	NULL
or	NULL
not	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
A23187	NULL
for	NULL
3	NULL
or	NULL
8	NULL
h	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
lysed	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
of	NULL
a	NULL
Promega	NULL
luciferase	NULL
assay	NULL
kit	NULL
.	NULL

The	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
for	NULL
30	NULL
s	NULL
with	NULL
a	NULL
Lumat	NULL
LB9501	NULL
luminometer	NULL
(	NULL
Berthold	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
and	NULL
EMSAs	NULL
.	NULL

For	NULL
nuclear	NULL
extracts	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
100	NULL
M	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
further	NULL
stimulated	NULL
for	NULL
1	NULL
,	NULL
4	NULL
,	NULL
or	NULL
8	NULL
additional	NULL
h	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
wM	NULL
A23187	NULL
.	NULL

PBLs	NULL
were	NULL
also	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
washed	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
with	NULL
hybridoma	NULL
culture	NULL
supernatant	NULL
of	NULL
anti-CD3	NULL
SPV-T3	NULL
MAb	NULL
(	NULL
62	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

Next	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
Dynabeads	NULL
M-450	NULL
coupled	NULL
to	NULL
sheep	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Dynal	NULL
A.S.	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
for	NULL
30	NULL
min	NULL
under	NULL
bidirectional	NULL
rotation	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
Dynabeads	NULL
with	NULL
T	NULL
cells	NULL
attached	NULL
were	NULL
collected	NULL
with	NULL
a	NULL
suitable	NULL
magnet	NULL
,	NULL
resuspended	NULL
in	NULL
ice-cold	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
at	NULL
4Â°C	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37Â°C	NULL
for	NULL
15	NULL
,	NULL
60	NULL
,	NULL
and	NULL
120	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PDTC	NULL
.	NULL

Small-scale	NULL
nuclear	NULL
extracts	NULL
were	NULL
then	NULL
prepared	NULL
according	NULL
to	NULL
a	NULL
procedure	NULL
described	NULL
elsewhere	NULL
(	NULL
54	NULL
)	NULL
with	NULL
some	NULL
modifications	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
400	NULL
pl	NULL
of	NULL
ice-cold	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
0.75	NULL
mM	NULL
spermidine	NULL
,	NULL
0.15	NULL
mM	NULL
spermine	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
[	NULL
DTT	NULL
]	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
[	NULL
PMSF	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
1	NULL
ug	NULL
of	NULL
pepstatin	NULL
per	NULL
ml	NULL
,	NULL
2	NULL
ug	NULL
each	NULL
of	NULL
leupeptin	NULL
and	NULL
aprotinin	NULL
per	NULL
ml	NULL
)	NULL
.	NULL

After	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
0.6	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
Nonidet	NULL
P-40	NULL
was	NULL
added	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
vortexed	NULL
and	NULL
centrifuged	NULL
in	NULL
a	NULL
microcentrifuge	NULL
for	NULL
30	NULL
s	NULL
at	NULL
15,000	NULL
x	NULL
g.	NULL
The	NULL
nuclear	NULL
pellet	NULL
was	NULL
extracted	NULL
with	NULL
50	NULL
ul	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
0.4	NULL
M	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
mM	NULL
Na	NULL
;	NULL
MoO	NULL
,	NULL
,	NULL
1	NULL
ag	NULL
of	NULL
pepstatin	NULL
per	NULL
ml	NULL
,	NULL
4	NULL
mg	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
4	NULL
ug	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
on	NULL
a	NULL
rocking	NULL
platform	NULL
and	NULL
further	NULL
centrifuged	NULL
at	NULL
15,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
and	NULL
stored	NULL
at	NULL
-80Â°C	NULL
.	NULL

All	NULL
steps	NULL
were	NULL
performed	NULL
on	NULL
ice	NULL
or	NULL
at	NULL
4Â°C	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
Bradford	NULL
assay	NULL
.	NULL

Gel	NULL
retardation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
18	NULL
)	NULL
with	NULL
some	NULL
modifications	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
1	NULL
to	NULL
5	NULL
ug	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
pg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
3	NULL
pl	NULL
of	NULL
5X	NULL
DNA	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
%	NULL
[	NULL
wt/vol	NULL
]	NULL
polivinylethanol	NULL
,	NULL
12.5	NULL
%	NULL
[	NULL
vol/vol	NULL
]	NULL
glycerol	NULL
,	NULL
50	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
8	NULL
]	NULL
,	NULL
2.5	NULL
mM	NULL
EDTA	NULL
,	NULL
2.5	NULL
mM	NULL
DTT	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
13	NULL
pl	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Next	NULL
,	NULL
25,000	NULL
cpm	NULL
(	NULL
2.5	NULL
x	NULL
10	NULL
``	NULL
to	NULL
5	NULL
X	NULL
10	NULL
``	NULL
cpm/ug	NULL
)	NULL
of	NULL
Â°Â°P-labeled	NULL
double-stranded	NULL
oligonucleotides	NULL
(	NULL
2	NULL
pl	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
this	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
40	NULL
min	NULL
.	NULL

In	NULL
competition	NULL
experiments	NULL
,	NULL
30-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
homologous	NULL
oligonucleotides	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
.	NULL

The	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
4	NULL
%	NULL
nondenatur-ing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
(	NULL
5	NULL
'	NULL
to	NULL
3	NULL
'	NULL
)	NULL
used	NULL
as	NULL
probes	NULL
in	NULL
EMSAs	NULL
were	NULL
gatcGGAGGAAAAACTGTITCATACAGAAGGCGT	NULL
(	NULL
distal	NULL
NFAT	NULL
site	NULL
of	NULL
human	NULL
IL-2	NULL
promoter	NULL
)	NULL
,	NULL
gatecGGGATTTCACCT	NULL
(	NULL
NF-kB	NULL
binding	NULL
site	NULL
of	NULL
human	NULL
IL-2	NULL
promoter	NULL
)	NULL
,	NULL
and	NULL
GCCCCCTCTGACTCATGCTG	NULL
ACA	NULL
(	NULL
nucleotides	NULL
-68	NULL
to	NULL
-46	NULL
,	NULL
including	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
CDZ7Â¢	NULL
promoter	NULL
)	NULL
.	NULL

The	NULL
pairs	NULL
of	NULL
complementary	NULL
synthetic	NULL
oligonucleotides	NULL
were	NULL
annealed	NULL
and	NULL
labeled	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
the	NULL
DNA	NULL
polymerase	NULL
I	NULL
(	NULL
for	NULL
NF-	NULL
Â«	NULL
B	NULL
and	NULL
NFAT	NULL
oligonucleotides	NULL
)	NULL
or	NULL
with	NULL
the	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcrip-tase	NULL
in	NULL
the	NULL
case	NULL
of	NULL
AP-1	NULL
oligonucleotide	NULL
.	NULL

Supershift	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
the	NULL
antiserum	NULL
(	NULL
0.5	NULL
wl	NULL
)	NULL
and	NULL
nuclear	NULL
extract	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4Â°C	NULL
,	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
.	NULL

The	NULL
antiserum	NULL
67.1	NULL
,	NULL
specific	NULL
for	NULL
NFAT1/p	NULL
,	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
.	NULL

After	NULL
the	NULL
different	NULL
treatments	NULL
,	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10Â°	NULL
)	NULL
were	NULL
washed	NULL
with	NULL
ice-cold	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
hypotonic	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-Cl	NULL
[	NULL
pH	NULL
7.5	NULL
]	NULL
,	NULL
containing	NULL
10	NULL
mM	NULL
NaCl	NULL
,	NULL
3	NULL
mM	NULL
MgCl	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
2	NULL
M	NULL
leupeptin	NULL
,	NULL
1	NULL
pg	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
centrifuged	NULL
at	NULL
650	NULL
x	NULL
g	NULL
to	NULL
pellet	NULL
the	NULL
nuclei	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
removed	NULL
.	NULL

The	NULL
nuclear	NULL
pellet	NULL
was	NULL
washed	NULL
in	NULL
the	NULL
hypotonic	NULL
buffer	NULL
without	NULL
detergent	NULL
and	NULL
resuspended	NULL
in	NULL
Laemmli	NULL
buffer	NULL
.	NULL

For	NULL
the	NULL
preparation	NULL
of	NULL
whole-cell	NULL
extracts	NULL
,	NULL
total	NULL
proteins	NULL
from	NULL
the	NULL
different	NULL
cells	NULL
(	NULL
10Â°	NULL
)	NULL
were	NULL
extracted	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Nuclear	NULL
and	NULL
total	NULL
extracts	NULL
were	NULL
boiled	NULL
and	NULL
separated	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
-polyacrylamide	NULL
(	NULL
6	NULL
%	NULL
)	NULL
gel	NULL
electrophoresis	NULL
under	NULL
reducing	NULL
conditions	NULL
.	NULL

Gels	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
that	NULL
were	NULL
incubated	NULL
in	NULL
blocking	NULL
solution	NULL
(	NULL
5	NULL
%	NULL
[	NULL
wt/vol	NULL
]	NULL
skim	NULL
milk	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
[	NULL
TBS	NULL
]	NULL
buffer	NULL
)	NULL
for	NULL
90	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
TBS-T	NULL
(	NULL
TBS	NULL
,	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
antiserum	NULL
67.1	NULL
(	NULL
0.03	NULL
%	NULL
[	NULL
vol/vol	NULL
]	NULL
)	NULL
in	NULL
TBS-T	NULL
for	NULL
2	NULL
h.	NULL
Membranes	NULL
were	NULL
then	NULL
washed	NULL
four	NULL
times	NULL
for	NULL
5	NULL
min	NULL
each	NULL
in	NULL
TBS-T	NULL
,	NULL
and	NULL
perox-idase-labeled	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
(	NULL
Pierce	NULL
)	NULL
was	NULL
incubated	NULL
for	NULL
90	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

After	NULL
three	NULL
washes	NULL
with	NULL
TBS-T	NULL
and	NULL
one	NULL
wash	NULL
with	NULL
H	NULL
,	NULL
O	NULL
,	NULL
mem-brane-bound	NULL
antibody	NULL
was	NULL
visualized	NULL
with	NULL
the	NULL
Amersham	NULL
ECL	NULL
(	NULL
enhanced	NULL
chemi-luminescence	NULL
)	NULL
detection	NULL
reagent	NULL
.	NULL

Solid-phase	NULL
JNK	NULL
assays	NULL
.	NULL

After	NULL
the	NULL
indicated	NULL
treatment	NULL
,	NULL
PBLs	NULL
(	NULL
5	NULL
X	NULL
10Â°	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
lysed	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
lysing	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
,	NULL
voL	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
10	NULL
mM	NULL
EGTA	NULL
,	NULL
40	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
2.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
20	NULL
pg	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
20	NULL
ag	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
12,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
and	NULL
incubated	NULL
with	NULL
0.3	NULL
ug	NULL
of	NULL
a	NULL
rabbit	NULL
polyclonal	NULL
anti-JNK-1	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

One	NULL
hour	NULL
after	NULL
this	NULL
incubation	NULL
,	NULL
protein	NULL
A	NULL
beads	NULL
were	NULL
added	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
4Â°C	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
h.	NULL
The	NULL
immune	NULL
complexes	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
that	NULL
contained	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
and	NULL
2	NULL
mM	NULL
vanadate	NULL
and	NULL
once	NULL
with	NULL
kinase	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
10	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
20	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mM	NULL
Na	NULL
,	NULL
;	NULL
VO	NULL
,	NULL
)	NULL
.	NULL

After	NULL
the	NULL
washing	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
the	NULL
kinase	NULL
reaction	NULL
was	NULL
initiated	NULL
by	NULL
addition	NULL
of	NULL
40	NULL
pl	NULL
of	NULL
kinase	NULL
buffer	NULL
containing	NULL
20	NULL
M	NULL
cold	NULL
ATP	NULL
,	NULL
0.1	NULL
@	NULL
Ci	NULL
of	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
GST-c-Jun	NULL
(	NULL
1-79	NULL
)	NULL
(	NULL
GST	NULL
is	NULL
glutathione	NULL
S-transferase	NULL
)	NULL
or	NULL
GST-NFATp	NULL
(	NULL
1-415	NULL
)	NULL
per	NULL
reaction	NULL
at	NULL
30Â°C	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
addition	NULL
of	NULL
10	NULL
pl	NULL
of	NULL
5	NULL
%	NULL
Laemmli	NULL
buffer	NULL
,	NULL
and	NULL
this	NULL
mixture	NULL
was	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
SDS	NULL
gel	NULL
electrophoresis	NULL
on	NULL
a	NULL
12	NULL
%	NULL
acrylamide	NULL
gel	NULL
.	NULL

GST-c-Jun	NULL
(	NULL
1-79	NULL
)	NULL
and	NULL
GST-NFATp	NULL
(	NULL
1-415	NULL
)	NULL
proteins	NULL
were	NULL
isolated	NULL
from	NULL
250	NULL
ml	NULL
of	NULL
bacterial	NULL
cultures	NULL
expressing	NULL
pGEX-c-Jun	NULL
(	NULL
1-79	NULL
)	NULL
plasmid	NULL
(	NULL
19	NULL
)	NULL
or	NULL
pGEX2T-NFATp	NULL
(	NULL
1-415	NULL
)	NULL
(	NULL
33	NULL
)	NULL
plasmid	NULL
,	NULL
respectively	NULL
,	NULL
with	NULL
GSH-Sepharose	NULL
4B	NULL
beads	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
.	NULL

,	NULL
Inc.	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
.	NULL

After	NULL
different	NULL
treatments	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
with	NULL
the	NULL
Ultraspec	NULL
system	NULL
(	NULL
Biotecx	NULL
Laboratories	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNAs	NULL
were	NULL
purified	NULL
by	NULL
using	NULL
the	NULL
PolyATtract	NULL
mRNA	NULL
isolation	NULL
system	NULL
III	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

For	NULL
Northern	NULL
blot	NULL
analysis	NULL
,	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
from	NULL
each	NULL
sample	NULL
(	NULL
0.5	NULL
pg	NULL
)	NULL
was	NULL
denatured	NULL
,	NULL
electrophoresed	NULL
on	NULL
a	NULL
1	NULL
%	NULL
formaldehyde	NULL
agarose	NULL
gel	NULL
,	NULL
and	NULL
blotted	NULL
onto	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
.	NULL

After	NULL
UV	NULL
cross-linking	NULL
,	NULL
the	NULL
filters	NULL
were	NULL
hybridized	NULL
overnight	NULL
at	NULL
42Â°C	NULL
with	NULL
the	NULL
corresponding	NULL
specific	NULL
probes	NULL
:	NULL
a	NULL
2.2-kb	NULL
EcoRI	NULL
fragment	NULL
of	NULL
the	NULL
NFATc	NULL
cDNA	NULL
(	NULL
40	NULL
)	NULL
,	NULL
a	NULL
0.8-kb	NULL
PsfI	NULL
fragment	NULL
of	NULL
IL-2	NULL
cDNA	NULL
,	NULL
a	NULL
0.8-kb	NULL
HindIII-PsfI	NULL
fragment	NULL
of	NULL
c-Jun	NULL
cDNA	NULL
,	NULL
and	NULL
a	NULL
0.6-kb	NULL
HindIII-BamHI	NULL
fragment	NULL
of	NULL
the	NULL
B-actin	NULL
cDNA	NULL
.	NULL

Immunocytochemical	NULL
localization	NULL
of	NULL
NFATp	NULL
and	NULL
NFATe	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
10Â°	NULL
)	NULL
were	NULL
electroporated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
pEF-BOS	NULL
NFAT1	NULL
plasmid	NULL
,	NULL
which	NULL
expresses	NULL
influenza	NULL
virus	NULL
hemagglutinin	NULL
(	NULL
HA	NULL
)	NULL
-tagged	NULL
NFATp	NULL
(	NULL
33	NULL
)	NULL
,	NULL
or	NULL
20	NULL
ug	NULL
of	NULL
pSH102CA418	NULL
(	NULL
provided	NULL
by	NULL
G.	NULL
Crabtree	NULL
)	NULL
,	NULL
which	NULL
expresses	NULL
HA-tagged	NULL
NFATc	NULL
(	NULL
1	NULL
to	NULL
418	NULL
)	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Forty-eight	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
plated	NULL
on	NULL
polylysine-coated	NULL
coverslips	NULL
and	NULL
either	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
incubated	NULL
with	NULL
PDTC	NULL
(	NULL
50	NULL
.M	NULL
)	NULL
for	NULL
2	NULL
h	NULL
before	NULL
stimulation	NULL
with	NULL
PMA	NULL
plus	NULL
Ca**	NULL
ionophore	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
subcellular	NULL
localization	NULL
of	NULL
NFATp	NULL
was	NULL
analyzed	NULL
by	NULL
immunofluorescence	NULL
with	NULL
anti-HA	NULL
antibody	NULL
(	NULL
12CA5	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
percentages	NULL
of	NULL
cells	NULL
displaying	NULL
nuclear	NULL
or	NULL
cytoplasmic	NULL
staining	NULL
were	NULL
scored	NULL
visually	NULL
after	NULL
counting	NULL
of	NULL
at	NULL
least	NULL
150	NULL
HA-expressing	NULL
cells	NULL
in	NULL
the	NULL
experiments	NULL
shown	NULL
.	NULL

Two	NULL
or	NULL
four	NULL
different	NULL
fields	NULL
are	NULL
presented	NULL
at	NULL
each	NULL
time	NULL
point	NULL
analyzed	NULL
.	NULL

RESULTS	NULL
Inhibition	NULL
of	NULL
T-cell	NULL
activation	NULL
by	NULL
DTCs	NULL
.	NULL

Signals	NULL
transduced	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
induce	NULL
the	NULL
synthesis	NULL
of	NULL
IL-2	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
receptors	NULL
(	NULL
IL-2Rs	NULL
)	NULL
and	NULL
other	NULL
activation	NULL
antigens	NULL
(	NULL
14	NULL
,	NULL
70	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
process	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
simultaneous	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
stimuli	NULL
that	NULL
activate	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
elevate	NULL
intracellular	NULL
Ca**	NULL
,	NULL
such	NULL
as	NULL
phorbol	NULL
esters	NULL
and	NULL
calcium	NULL
ionophores	NULL
(	NULL
15	NULL
,	NULL
67	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
different	NULL
antioxidants	NULL
on	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
,	NULL
flow	NULL
cytometry	NULL
analysis	NULL
of	NULL
Jurkat	NULL
cells	NULL
activated	NULL
with	NULL
the	NULL
phorbol	NULL
ester	NULL
PMA	NULL
and	NULL
the	NULL
calcium	NULL
ionophore	NULL
A23187	NULL
,	NULL
either	NULL
preincubated	NULL
or	NULL
not	NULL
with	NULL
different	NULL
DTCs	NULL
,	NULL
PDTC	NULL
,	NULL
or	NULL
DDTC	NULL
and	NULL
its	NULL
disulfide-linked	NULL
form	NULL
disulfiram	NULL
,	NULL
were	NULL
carried	NULL
out	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
doses	NULL
of	NULL
DTCs	NULL
in	NULL
the	NULL
range	NULL
of	NULL
50	NULL
to	NULL
100	NULL
mM	NULL
inhibited	NULL
the	NULL
upregulated	NULL
expression	NULL
of	NULL
the	NULL
T-cell	NULL
activation	NULL
antigen	NULL
CD69	NULL
and	NULL
the	NULL
IL-2Ra	NULL
Â«	NULL
chain	NULL
(	NULL
CD25	NULL
)	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

The	NULL
pretreatment	NULL
with	NULL
DTCs	NULL
strongly	NULL
inhibited	NULL
the	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
CD25	NULL
,	NULL
whereas	NULL
that	NULL
of	NULL
CD69	NULL
was	NULL
not	NULL
totally	NULL
blocked	NULL
.	NULL

Conversely	NULL
,	NULL
DTCs	NULL
induced	NULL
low	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
CD69	NULL
that	NULL
persisted	NULL
but	NULL
were	NULL
not	NULL
further	NULL
increased	NULL
by	NULL
subsequent	NULL
stimulation	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
using	NULL
unfrac-tionated	NULL
PBLs	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
,	NULL
and	NULL
inhibition	NULL
of	NULL
CD69	NULL
membrane	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
the	NULL
T-cell	NULL
population	NULL
activated	NULL
through	NULL
the	NULL
CD3-TCR	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
synthesis	NULL
of	NULL
IL-2	NULL
requires	NULL
the	NULL
efficient	NULL
integration	NULL
of	NULL
signals	NULL
transmitted	NULL
through	NULL
different	NULL
pathways	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

We	NULL
next	NULL
explored	NULL
whether	NULL
the	NULL
inhibitory	NULL
effects	NULL
observed	NULL
with	NULL
the	NULL
DTCs	NULL
were	NULL
also	NULL
reflected	NULL
at	NULL
the	NULL
IL-2	NULL
expression	NULL
level	NULL
.	NULL

The	NULL
IL-2	NULL
secretion	NULL
by	NULL
Jurkat	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
DITHIOCARBAMATES	NULL
BLOCK	NULL
NFAT	NULL
ACTIVATION	NULL
-	NULL
6439	NULL
A	NULL
CD69	NULL
CD25	NULL
PDTC	NULL
s	NULL
do	NULL
is	NULL
zo	NULL
0	NULL
5	NULL
40	NULL
45	NULL
20	NULL
DDTC	NULL
C	NULL
EL	NULL
L_	NULL
NU	NULL
M	NULL
BER	NULL
Disulfiram	NULL
0	NULL
5	NULL
do	NULL
as	NULL
20	NULL
0	NULL
Â§	NULL
do	NULL
dS	NULL
20	NULL
a	NULL
ï¬	NULL
*	NULL
u	NULL
â	NULL
a	NULL
10Â°	NULL
19Â°	NULL
10	NULL
l	NULL
10	NULL
1	NULL
a	NULL
10	NULL
!	NULL

10Â°	NULL
LOG	NULL
FLUORESCENCE	NULL
INTENSITY	NULL
P+Io	NULL
anti-CD3	NULL
PDTC	NULL
CELL	NULL
NUMBER	NULL
0	NULL
10	NULL
zo	NULL
so	NULL
40	NULL
se	NULL
0	NULL
40	NULL
20	NULL
an	NULL
ao	NULL
so	NULL
(	NULL
10Â°	NULL
10	NULL
a	NULL
LOG	NULL
FLUORESCENCE	NULL
INTENSITY	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Effect	NULL
of	NULL
DTCs	NULL
on	NULL
membrane	NULL
expression	NULL
of	NULL
T-cell	NULL
activation	NULL
markers	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Flow	NULL
cytometry	NULL
profiles	NULL
of	NULL
CD69	NULL
and	NULL
CD25	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
different	NULL
DTCs	NULL
(	NULL
thin	NULL
lines	NULL
)	NULL
are	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
Ca**	NULL
ionophore	NULL
(	NULL
thick	NULL
lines	NULL
)	NULL
or	NULL
cells	NULL
pretreated	NULL
with	NULL
the	NULL
DTCs	NULL
for	NULL
2	NULL
h	NULL
and	NULL
further	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
(	NULL
dotted	NULL
lines	NULL
)	NULL
.	NULL

In	NULL
the	NULL
control	NULL
panel	NULL
(	NULL
-	NULL
)	NULL
dotted	NULL
lines	NULL
indicated	NULL
the	NULL
staining	NULL
with	NULL
P3X63	NULL
myeloma	NULL
supernatant	NULL
,	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
,	NULL
and	NULL
thin	NULL
lines	NULL
indicate	NULL
the	NULL
baseline	NULL
expression	NULL
of	NULL
CD69	NULL
or	NULL
CD25	NULL
.	NULL

DTCs	NULL
were	NULL
added	NULL
for	NULL
16	NULL
h	NULL
at	NULL
doses	NULL
of	NULL
100	NULL
M	NULL
(	NULL
PDTC	NULL
and	NULL
DDTC	NULL
)	NULL
and	NULL
50	NULL
M	NULL
(	NULL
disulfiram	NULL
)	NULL
.	NULL

PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
and	NULL
Ca**	NULL
fonophore	NULL
A23187	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
were	NULL
also	NULL
added	NULL
for	NULL
16	NULL
h.	NULL
(	NULL
B	NULL
)	NULL
Profiles	NULL
of	NULL
CD69	NULL
expression	NULL
in	NULL
PBLs	NULL
untreated	NULL
or	NULL
pretreated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
50	NULL
uM	NULL
PDTC	NULL
and	NULL
further	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
M	NULL
ionophore	NULL
or	NULL
by	NULL
incubation	NULL
in	NULL
UCHT.1	NULL
(	NULL
anti-CD3	NULL
)	NULL
-coated	NULL
cells	NULL
(	NULL
thin	NULL
lines	NULL
)	NULL
are	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
or	NULL
immobilized	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
thick	NULL
lines	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
reagents	NULL
for	NULL
16	NULL
h.	NULL
The	NULL
dotted	NULL
lines	NULL
indicated	NULL
the	NULL
staining	NULL
with	NULL
anti-ELAM	NULL
antibody	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

PMA	NULL
plus	NULL
ionophore	NULL
was	NULL
inhibited	NULL
,	NULL
in	NULL
a	NULL
dose-dependent	NULL
man-ner	NULL
,	NULL
by	NULL
the	NULL
different	NULL
antioxidants	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

DTCs	NULL
also	NULL
blocked	NULL
IL-2	NULL
secretion	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
20	NULL
to	NULL
50	NULL
pM	NULL
.	NULL

Since	NULL
DDTC	NULL
and	NULL
disulfiram	NULL
,	NULL
but	NULL
not	NULL
PDTC	NULL
,	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
produce	NULL
acidification	NULL
in	NULL
long-term-treated	NULL
cell	NULL
cultures	NULL
(	NULL
53	NULL
)	NULL
and	NULL
PDTC	NULL
displayed	NULL
a	NULL
very	NULL
potent	NULL
inhibitory	NULL
effect	NULL
on	NULL
membrane	NULL
expression	NULL
of	NULL
T-cell	NULL
activation	NULL
markers	NULL
and	NULL
IL-2	NULL
secretion	NULL
,	NULL
we	NULL
used	NULL
this	NULL
derivative	NULL
of	NULL
DTC	NULL
to	NULL
further	NULL
characterize	NULL
the	NULL
mechanism	NULL
accounting	NULL
for	NULL
the	NULL
interference	NULL
with	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
observed	NULL
.	NULL

Blockade	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
DTCs	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
IL-2	NULL
secretion	NULL
by	NULL
DTCs	NULL
,	NULL
we	NULL
performed	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
Jurkat	NULL
cells	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
PDTC	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

IL-2	NULL
mRNA	NULL
steady-state	NULL
levels	NULL
,	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
and	NULL
strongly	NULL
increased	NULL
after	NULL
8	NULL
h	NULL
of	NULL
stimulation	NULL
,	NULL
were	NULL
totally	NULL
abrogated	NULL
in	NULL
cells	NULL
exposed	NULL
to	NULL
PDTC	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

The	NULL
6440	NULL
MARTINEZ-MARTINEZ	NULL
ET	NULL
AL	NULL
.	NULL

ro	NULL
.	NULL

000	NULL
Â«	NULL
500	NULL
IL-2	NULL
(	NULL
pg/ml	NULL
)	NULL
.000	NULL
500	NULL
Prto	NULL
Â°	NULL
--	NULL
-	NULL
Fu	NULL
oto	NULL
oR	NULL
o	NULL
+	NULL
~	NULL
PDTC	NULL
___	NULL
DDTC	NULL
_-	NULL
Disulfiram	NULL
ï¬mxem	NULL
â	NULL
sï¬	NULL
5,96st	NULL
%	NULL
aP	NULL
(	NULL
aM	NULL
)	NULL
(	NULL
am	NULL
)	NULL
(	NULL
M	NULL
)	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
by	NULL
DTCs	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
either	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
the	NULL
indicated	NULL
micromolar	NULL
concentrations	NULL
of	NULL
DTCs	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
were	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
uM	NULL
Ca**	NULL
ionophore	NULL
A23187	NULL
(	NULL
P+I0	NULL
)	NULL
.	NULL

IL-2	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
supernatants	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
20	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IL-2	NULL
detected	NULL
in	NULL
supernatant	NULL
of	NULL
cells	NULL
single	NULL
treated	NULL
with	NULL
the	NULL
different	NULL
DTCs	NULL
were	NULL
the	NULL
same	NULL
as	NULL
those	NULL
in	NULL
the	NULL
control	NULL
cells	NULL
(	NULL
<	NULL
60	NULL
pg/ml	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
represented	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
standard	NULL
deviation	NULL
of	NULL
two	NULL
independent	NULL
measures	NULL
.	NULL

Cell	NULL
viability	NULL
,	NULL
tested	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
just	NULL
before	NULL
collection	NULL
of	NULL
the	NULL
supernatants	NULL
,	NULL
was	NULL
higher	NULL
than	NULL
90	NULL
%	NULL
for	NULL
the	NULL
different	NULL
treatments	NULL
.	NULL

treatment	NULL
with	NULL
PDTC	NULL
did	NULL
not	NULL
result	NULL
in	NULL
nonspecific	NULL
or	NULL
toxic	NULL
inhibition	NULL
of	NULL
gene	NULL
expression	NULL
;	NULL
rehybridization	NULL
of	NULL
the	NULL
blotted	NULL
membrane	NULL
with	NULL
a	NULL
c-jun	NULL
probe	NULL
revealed	NULL
that	NULL
PDTC	NULL
triggered	NULL
a	NULL
simultaneous	NULL
and	NULL
sustained	NULL
induction	NULL
of	NULL
the	NULL
c-jun	NULL
transcripts	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
c-jun	NULL
mRNA	NULL
levels	NULL
were	NULL
synergistically	NULL
increased	NULL
by	NULL
treatment	NULL
with	NULL
PDTC	NULL
plus	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionophore	NULL
under	NULL
conditions	NULL
in	NULL
which	NULL
IL-2	NULL
transcription	NULL
was	NULL
completely	NULL
abolished	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
proximal	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
containing	NULL
275	NULL
bp	NULL
of	NULL
the	NULL
upstream	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
)	NULL
includes	NULL
binding	NULL
sites	NULL
for	NULL
a	NULL
number	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
mediate	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
15	NULL
)	NULL
,	NULL
we	NULL
next	NULL
studied	NULL
whether	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
DTCs	NULL
on	NULL
IL-2	NULL
transcriptional	NULL
expression	NULL
were	NULL
mediated	NULL
through	NULL
inhibition	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
reporter	NULL
plasmid	NULL
containing	NULL
the	NULL
IL-2	NULL
promoter	NULL
region	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
plus	NULL
ionophore	NULL
was	NULL
abrogated	NULL
by	NULL
treatment	NULL
with	NULL
PDTC	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
DDTC	NULL
,	NULL
or	NULL
disulfiram	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effects	NULL
of	NULL
PDTC	NULL
on	NULL
different	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

We	NULL
further	NULL
dissected	NULL
the	NULL
mechanisms	NULL
responsible	NULL
for	NULL
the	NULL
PDTC-mediated	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
analyzing	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
DTC	NULL
on	NULL
the	NULL
activity	NULL
and	NULL
binding	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
AP-1	NULL
,	NULL
NF-kB	NULL
,	NULL
and	NULL
NFAT	NULL
,	NULL
which	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
15	NULL
,	NULL
26	NULL
,	NULL
46	NULL
)	NULL
.	NULL

As	NULL
described	NULL
for	NULL
other	NULL
stimuli	NULL
(	NULL
52	NULL
,	NULL
53	NULL
)	NULL
,	NULL
the	NULL
potent	NULL
activation	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
of	NULL
the	NULL
NF-kB	NULL
reporter	NULL
construct	NULL
was	NULL
blocked	NULL
by	NULL
pretreatment	NULL
with	NULL
PDTC	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
upper	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
an	NULL
AP-1-dependent	NULL
reporter	NULL
plasmid	NULL
,	NULL
which	NULL
is	NULL
stimulated	NULL
by	NULL
PDTC	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
,	NULL
was	NULL
synergistically	NULL
increased	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
plus	NULL
ionophore	NULL
and	NULL
PDTC	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
AP-1	NULL
cooperates	NULL
with	NULL
NFAT	NULL
to	NULL
activate	NULL
transcription	NULL
through	NULL
the	NULL
NFAT	NULL
distal	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
inter-estingly	NULL
,	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
reporter	NULL
construct	NULL
directed	NULL
by	NULL
this	NULL
NFAT	NULL
motif	NULL
was	NULL
abrogated	NULL
by	NULL
PDTC	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lower	NULL
)	NULL
.	NULL

The	NULL
data	NULL
obtained	NULL
in	NULL
these	NULL
transfection	NULL
experiments	NULL
correlated	NULL
with	NULL
the	NULL
effect	NULL
of	NULL
PDTC	NULL
on	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL..	NULL
PDTC	NULL
P+lo	NULL
P+o/PDTC	NULL
PDTC	NULL
P+lo	NULL
P+I0/PDTC	NULL
PDTC	NULL
P+lo	NULL
P+1o/PDTC	NULL
#	NULL
__	NULL
.	NULL

Â©	NULL
IL-2	NULL
c-jun	NULL
f-actin	NULL
&	NULL
IL-2	NULL
Luc	NULL
transcriptional	NULL
activity	NULL
(	NULL
R.L.V	NULL
.	NULL

10	NULL
5	NULL
o	NULL
lad	NULL
+	NULL
Aa	NULL
PDTC	NULL
PDTC/P+Io	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
PDTC	NULL
on	NULL
IL-2	NULL
transcription	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
with	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNAs	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
PDTC	NULL
or	NULL
PMA	NULL
plus	NULL
A23187	NULL
(	NULL
P+I0	NULL
)	NULL
or	NULL
pretreated	NULL
with	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
A23187	NULL
(	NULL
P+1I0/PDTC	NULL
)	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

After	NULL
agarose	NULL
electrophoresis	NULL
and	NULL
blotting	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
sequentially	NULL
hybridized	NULL
with	NULL
IL-2	NULL
,	NULL
c-Jun	NULL
,	NULL
and	NULL
B-actin	NULL
probes	NULL
as	NULL
indicated	NULL
.	NULL

C	NULL
,	NULL
control	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
transcriptional	NULL
activity	NULL
of	NULL
IL-2	NULL
promoter	NULL
(	NULL
bp	NULL
-326	NULL
to	NULL
+45	NULL
)	NULL
was	NULL
tested	NULL
by	NULL
transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
Lipofectin	NULL
for	NULL
8	NULL
h.	NULL
Thirty-six	NULL
hours	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PDTC	NULL
or	NULL
PMA	NULL
plus	NULL
ionophore	NULL
(	NULL
P+I0	NULL
)	NULL
or	NULL
were	NULL
preincubated	NULL
with	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
further	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
(	NULL
PDTC/P+I0	NULL
)	NULL
for	NULL
8	NULL
h.	NULL
The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
R.L.U	NULL
.	NULL
)	NULL

measured	NULL
for	NULL
30	NULL
s.	NULL
Results	NULL
are	NULL
representative	NULL
of	NULL
five	NULL
independent	NULL
experiments	NULL
.	NULL

PDTC	NULL
(	NULL
50	NULL
M	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
Ca**	NULL
ionophore	NULL
(	NULL
1	NULL
M	NULL
)	NULL
were	NULL
used	NULL
at	NULL
the	NULL
same	NULL
doses	NULL
in	NULL
single	NULL
or	NULL
combined	NULL
treatments	NULL
in	NULL
panels	NULL
A	NULL
and	NULL
B.	NULL
such	NULL
transcription	NULL
factors	NULL
analyzed	NULL
by	NULL
EMSAs	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
specific	NULL
binding	NULL
to	NULL
NF-	NULL
Â«	NULL
xB	NULL
and	NULL
NFAT	NULL
probes	NULL
from	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
,	NULL
strongly	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
,	NULL
was	NULL
inhibited	NULL
by	NULL
DTC	NULL
,	NULL
whereas	NULL
AP-1	NULL
DNA-binding	NULL
activity	NULL
was	NULL
stimulated	NULL
by	NULL
PDTC	NULL
with	NULL
the	NULL
same	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

These	NULL
effects	NULL
were	NULL
not	NULL
due	NULL
to	NULL
a	NULL
direct	NULL
interference	NULL
of	NULL
PDTC	NULL
with	NULL
DNA-transcription	NULL
factor	NULL
interaction	NULL
,	NULL
since	NULL
exogenous	NULL
addition	NULL
of	NULL
PDTC	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixtures	NULL
in	NULL
EMSAs	NULL
,	NULL
even	NULL
at	NULL
concentrations	NULL
of	NULL
100	NULL
pM	NULL
,	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
specific	NULL
complexes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
PDTC	NULL
on	NULL
NF-	NULL
Â«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
PBLs	NULL
activated	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
PDTC	NULL
completely	NULL
blocked	NULL
the	NULL
specific	NULL
binding	NULL
to	NULL
the	NULL
voL	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
A	NULL
500	NULL
1	NULL
PDTC	NULL
|	NULL
P+lo	NULL
DITHIOCARBAMATES	NULL
BLOCK	NULL
NFAT	NULL
ACTIVATION	NULL
-	NULL
6441	NULL
|_	NULL
PDTC/P+Ho	NULL
1	NULL
PDTC/P+Io	NULL
1	NULL
PDTC	NULL
1	NULL
P+lo	NULL
|_	NULL
PDTC/P+He	NULL
+	NULL
PDTC	NULL
+	NULL
P+lo	NULL
1	NULL
PDTC	NULL
1	NULL
P+lo	NULL
+	NULL
PDTC	NULL
+	NULL
P+lo	NULL
+	NULL
PDTC	NULL
+	NULL
P+lo	NULL
400	NULL
NFkB	NULL
transcriptional	NULL
activity	NULL
(	NULL
R.L.V	NULL
.	NULL
)	NULL

10	NULL
3	NULL
P+lo	NULL
PDTC	NULL
PDTC/P+Io	NULL
40	NULL
so	NULL
20	NULL
NFAT	NULL
transcriptional	NULL
activity	NULL
(	NULL
R.L.UV	NULL
.	NULL
)	NULL

103	NULL
2	NULL
C	NULL
1	NULL
P+lo	NULL
PDTC	NULL
PDTC/P+o	NULL
AP-1	NULL
NFkB	NULL
anti-	NULL
CD3	NULL
PDTC/anti-CD3	NULL
60	NULL
120	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

PDTC-mediated	NULL
changes	NULL
in	NULL
the	NULL
activity	NULL
and	NULL
DNA	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Transcriptional	NULL
activities	NULL
of	NULL
NF-	NULL
Â«	NULL
B-	NULL
and	NULL
NFAT-dependent	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
were	NULL
analyzed	NULL
by	NULL
transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
and	NULL
treated	NULL
with	NULL
PDTC	NULL
or	NULL
PMA	NULL
plus	NULL
ionophore	NULL
or	NULL
were	NULL
pretreated	NULL
with	NULL
PDTC	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
with	NULL
the	NULL
same	NULL
doses	NULL
and	NULL
conditions	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

(	NULL
B	NULL
)	NULL
DNA-binding	NULL
activities	NULL
of	NULL
NFAT	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
factors	NULL
were	NULL
analyzed	NULL
with	NULL
the	NULL
same	NULL
pools	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
100	NULL
M	NULL
PDTC	NULL
or	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
M	NULL
ionophore	NULL
(	NULL
P+I0	NULL
)	NULL
for	NULL
4	NULL
h.	NULL
For	NULL
the	NULL
combined	NULL
treatment	NULL
(	NULL
PDTC/P+I0	NULL
)	NULL
,	NULL
PDTC	NULL
was	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
4-h	NULL
stimulation	NULL
with	NULL
P+Io	NULL
at	NULL
the	NULL
same	NULL
doses	NULL
as	NULL
those	NULL
used	NULL
in	NULL
separate	NULL
treatments	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
tested	NULL
by	NULL
addition	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixtures	NULL
of	NULL
30-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
homologous	NULL
oligonucleotide	NULL
(	NULL
Comp	NULL
.	NULL

+	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
was	NULL
analyzed	NULL
for	NULL
nuclear	NULL
extracts	NULL
from	NULL
purified	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
cross-linked	NULL
T3b	NULL
anti-CD3	NULL
antibody	NULL
for	NULL
15	NULL
,	NULL
60	NULL
,	NULL
and	NULL
120	NULL
min	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
with	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
further	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
PDTC/anti-CD3	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

NFAT	NULL
probe	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
both	NULL
PBLs	NULL
activated	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
and	NULL
T	NULL
cells	NULL
stimulated	NULL
by	NULL
cross-linking	NULL
with	NULL
immobilized	NULL
T3b	NULL
anti-CD3	NULL
MAb	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mechanisms	NULL
of	NULL
inhibition	NULL
of	NULL
NFAT	NULL
by	NULL
PDTC	NULL
.	NULL

The	NULL
possible	NULL
effects	NULL
of	NULL
DTC	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
NFAT	NULL
cytosolic	NULL
component	NULL
that	NULL
could	NULL
account	NULL
for	NULL
the	NULL
observed	NULL
inhibition	NULL
were	NULL
analyzed	NULL
.	NULL

Other	NULL
drugs	NULL
which	NULL
block	NULL
the	NULL
binding	NULL
and	NULL
transactivating	NULL
abilities	NULL
of	NULL
NFAT	NULL
,	NULL
such	NULL
as	NULL
CsA	NULL
and	NULL
FK	NULL
506	NULL
,	NULL
target	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
,	NULL
thus	NULL
preventing	NULL
the	NULL
subsequent	NULL
dephosphorylation	NULL
and	NULL
translocation	NULL
of	NULL
cytosolic	NULL
NFAT	NULL
(	NULL
28	NULL
,	NULL
55	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
explored	NULL
whether	NULL
PDTC	NULL
affected	NULL
the	NULL
dephosphorylation	NULL
of	NULL
NFAT1/p	NULL
and	NULL
its	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
upon	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
fractionated	NULL
cellular	NULL
extracts	NULL
indicated	NULL
that	NULL
treatment	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
or	NULL
ionophore	NULL
alone	NULL
induced	NULL
the	NULL
dephosphorylation	NULL
and	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
of	NULL
NFAT	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
(	NULL
29	NULL
,	NULL
49	NULL
,	NULL
60	NULL
,	NULL
65	NULL
)	NULL
,	NULL
the	NULL
dephosphorylation	NULL
or	NULL
translocation	NULL
of	NULL
NFAT	NULL
was	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
5	NULL
min	NULL
,	NULL
maintained	NULL
for	NULL
at	NULL
least	NULL
90	NULL
min	NULL
,	NULL
and	NULL
blocked	NULL
by	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
exposure	NULL
of	NULL
cells	NULL
to	NULL
PDTC	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
ionophore	NULL
or	NULL
PMA	NULL
plus	NULL
ionophore	NULL
resulted	NULL
in	NULL
transient	NULL
dephosphorylation	NULL
and	NULL
translocation	NULL
of	NULL
NFATp	NULL
,	NULL
and	NULL
the	NULL
bulk	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
was	NULL
found	NULL
in	NULL
the	NULL
cytosolic	NULL
extracts	NULL
,	NULL
after	NULL
90	NULL
min	NULL
of	NULL
single	NULL
or	NULL
combined	NULL
treatment	NULL
with	NULL
PDTC	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
the	NULL
mobility	NULL
of	NULL
NFATp	NULL
exported	NULL
from	NULL
the	NULL
nucleus	NULL
of	NULL
PDTC-treated	NULL
cells	NULL
was	NULL
lower	NULL
than	NULL
that	NULL
displayed	NULL
by	NULL
the	NULL
phosphorylated	NULL
form	NULL
in	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

To	NULL
further	NULL
analyze	NULL
the	NULL
effects	NULL
of	NULL
PDTC	NULL
on	NULL
the	NULL
nuclear	NULL
shuttling	NULL
of	NULL
NFATp	NULL
,	NULL
we	NULL
performed	NULL
immunocytochemical	NULL
experiments	NULL
in	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
HA-tagged	NULL
full-length	NULL
NFATp	NULL
(	NULL
33	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
HA-tagged	NULL
recombinant	NULL
NFATp	NULL
was	NULL
found	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
unstimulated	NULL
cells	NULL
and	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
pretreatment	NULL
with	NULL
PDTC	NULL
promoted	NULL
a	NULL
rapid	NULL
nuclear	NULL
export	NULL
of	NULL
NFATp	NULL
from	NULL
the	NULL
nucleus	NULL
of	NULL
cells	NULL
activated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
tagged	NULL
recombinant	NULL
NFATp	NULL
protein	NULL
was	NULL
already	NULL
detected	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
~50	NULL
%	NULL
of	NULL
the	NULL
transfected	NULL
cells	NULL
after	NULL
30	NULL
min	NULL
of	NULL
activation	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
export	NULL
was	NULL
complete	NULL
by	NULL
90	NULL
min	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
PDTC	NULL
,	NULL
by	NULL
mechanisms	NULL
at	NULL
present	NULL
6442	NULL
MARTINEZ-MARTINEZ	NULL
ET	NULL
AL	NULL
.	NULL

P+1o/PDTC	NULL
P+lo	NULL
o	NULL
o	NULL
5	NULL
90	NULL
5	NULL
90	NULL
5	NULL
90	NULL
5	NULL
90	NULL
Io/PDTC	NULL
tn	NULL
P+Io/CsA	NULL
tn	NULL
1o/CsA	NULL
min	NULL
-	NULL
|	NULL
&	NULL
-	NULL
Â»	NULL
â	NULL
ï¬r	NULL
â	NULL
?	NULL

Wes	NULL
|	NULL
1,11	NULL
,	NULL
--	NULL
*	NULL
to-	NULL
c	NULL
aome	NULL
Gime	NULL
~	NULL
+	NULL
Fal	NULL
*	NULL
NUCLEAR	NULL
-	NULL
Â»	NULL
-	NULL
Â»	NULL
P	NULL
``	NULL
Unstimulated	NULL
PMA	NULL
+	NULL
ionomycin	NULL
30	NULL
min	NULL
90	NULL
min	NULL
PDTC	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Rapid	NULL
shuttling	NULL
of	NULL
NFATp	NULL
induced	NULL
by	NULL
PDTC	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
fractionated	NULL
cell	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
10Â°	NULL
per	NULL
line	NULL
in	NULL
nuclear	NULL
lysates	NULL
and	NULL
5	NULL
X	NULL
10Â°	NULL
for	NULL
total	NULL
lysates	NULL
)	NULL
treated	NULL
for	NULL
5	NULL
or	NULL
90	NULL
min	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
aM	NULL
ionophore	NULL
or	NULL
1	NULL
M	NULL
ionophore	NULL
alone	NULL
either	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
PDTC	NULL
(	NULL
100	NULL
wM	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
2	NULL
and	NULL
1	NULL
h	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
antiserum	NULL
67.1	NULL
was	NULL
used	NULL
for	NULL
NFAT1/p	NULL
detection	NULL
.	NULL

The	NULL
electrophoretic	NULL
mobilities	NULL
of	NULL
the	NULL
upper	NULL
and	NULL
lower	NULL
bands	NULL
corresponding	NULL
to	NULL
the	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
forms	NULL
of	NULL
NFAT1	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

C	NULL
,	NULL
control	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Immunocytochemical	NULL
staining	NULL
of	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
HA-tagged	NULL
NFATp	NULL
either	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
incubated	NULL
with	NULL
PDTC	NULL
(	NULL
50	NULL
wM	NULL
)	NULL
for	NULL
2	NULL
bh	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
ionomycin	NULL
(	NULL
3	NULL
uM	NULL
)	NULL
(	NULL
PMA	NULL
+ionomycin	NULL
)	NULL
for	NULL
30	NULL
or	NULL
90	NULL
min	NULL
,	NULL
fixed	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
immunofluorescence	NULL
with	NULL
anti-HA	NULL
antibody	NULL
.	NULL

The	NULL
upper	NULL
panel	NULL
shows	NULL
the	NULL
subcellular	NULL
localization	NULL
of	NULL
HA-tagged	NULL
NFATp	NULL
in	NULL
resting	NULL
and	NULL
stimulated	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
lower	NULL
panel	NULL
corresponds	NULL
to	NULL
stimulation	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
in	NULL
PDTC-pretreated	NULL
cells	NULL
.	NULL

unknown	NULL
,	NULL
accelerates	NULL
the	NULL
shuttling	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
requirement	NULL
of	NULL
sustained	NULL
activation	NULL
to	NULL
promote	NULL
NFAT-dependent	NULL
transcription	NULL
(	NULL
65	NULL
)	NULL
,	NULL
we	NULL
next	NULL
investigated	NULL
whether	NULL
PDTC	NULL
affected	NULL
the	NULL
transactivating	NULL
ability	NULL
of	NULL
NFAT	NULL
in	NULL
activated	NULL
cells	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
we	NULL
performed	NULL
co-transfection	NULL
experiments	NULL
with	NULL
a	NULL
chimeric	NULL
expression	NULL
plasmid	NULL
encoding	NULL
the	NULL
NH	NULL
,	NULL
-terminal	NULL
transactivation	NULL
domain	NULL
of	NULL
NFATp	NULL
fused	NULL
to	NULL
the	NULL
GAL4	NULL
DBD	NULL
(	NULL
32	NULL
)	NULL
,	NULL
together	NULL
with	NULL
a	NULL
GAL4-Luc	NULL
reporter	NULL
plasmid	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
PDTC	NULL
prevented	NULL
the	NULL
transactivation	NULL
function	NULL
of	NULL
NFATp	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

As	NULL
controls	NULL
,	NULL
in	NULL
parallel	NULL
transfections	NULL
,	NULL
we	NULL
included	NULL
GALA	NULL
expression	NULL
vectors	NULL
encoding	NULL
the	NULL
transactivation	NULL
domain	NULL
of	NULL
c-Jun	NULL
(	NULL
GAL4-c-Jun	NULL
wild	NULL
type	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
PDTC	NULL
inhibited	NULL
the	NULL
transactivation	NULL
by	NULL
the	NULL
GALA-NFAT	NULL
hybrid	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionophore	NULL
,	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
that	NULL
strongly	NULL
increased	NULL
the	NULL
transactivation	NULL
by	NULL
the	NULL
GAL4-c-Jun	NULL
construct	NULL
.	NULL

As	NULL
occurred	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
an	NULL
AP-1	NULL
reporter	NULL
construct	NULL
,	NULL
PDTC	NULL
and	NULL
PMA-ionophore	NULL
strongly	NULL
synergized	NULL
activating	NULL
the	NULL
GAL4-c-Jun	NULL
construct	NULL
.	NULL

As	NULL
an	NULL
additional	NULL
control	NULL
,	NULL
we	NULL
also	NULL
included	NULL
in	NULL
the	NULL
experiments	NULL
a	NULL
plasmid	NULL
identical	NULL
to	NULL
the	NULL
GALA4-c-Jun	NULL
wild	NULL
type	NULL
but	NULL
double	NULL
mutated	NULL
in	NULL
serines	NULL
located	NULL
at	NULL
positions	NULL
63	NULL
and	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL..	NULL
73	NULL
(	NULL
GAL4-c-Jun	NULL
S	NULL
,	NULL
;	NULL
+	NULL
S	NULL
,	NULL
)	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Transactivation	NULL
by	NULL
this	NULL
mutated	NULL
plasmid	NULL
was	NULL
not	NULL
affected	NULL
at	NULL
all	NULL
by	NULL
treatments	NULL
with	NULL
the	NULL
stimuli	NULL
that	NULL
strongly	NULL
increased	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
whether	NULL
the	NULL
effect	NULL
of	NULL
PDTC	NULL
on	NULL
the	NULL
rapid	NULL
nuclear	NULL
export	NULL
of	NULL
NFATp	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
was	NULL
also	NULL
operative	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
we	NULL
carried	NULL
out	NULL
Western	NULL
blotting	NULL
experiments	NULL
with	NULL
the	NULL
y8	NULL
T-cell	NULL
line	NULL
PEER	NULL
as	NULL
well	NULL
as	NULL
with	NULL
PBLs	NULL
.	NULL

The	NULL
phosphorylated	NULL
status	NULL
of	NULL
NFATp	NULL
was	NULL
monitored	NULL
after	NULL
different	NULL
times	NULL
of	NULL
activation	NULL
with	NULL
ionophore	NULL
in	NULL
fractionated	NULL
cellular	NULL
extracts	NULL
of	NULL
control	NULL
and	NULL
PDTC-treated	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
pretreatment	NULL
of	NULL
PBL	NULL
and	NULL
PEER	NULL
cells	NULL
with	NULL
PDTC	NULL
resulted	NULL
in	NULL
a	NULL
rapid	NULL
export	NULL
of	NULL
NFATp	NULL
with	NULL
a	NULL
kinetics	NULL
similar	NULL
to	NULL
that	NULL
displayed	NULL
by	NULL
Jurkat	NULL
cells	NULL
.	NULL

Similarly	NULL
,	NULL
treatment	NULL
with	NULL
the	NULL
Ca**	NULL
ionophore	NULL
induced	NULL
the	NULL
sustained	NULL
presence	NULL
of	NULL
the	NULL
dephosphorylated	NULL
form	NULL
in	NULL
the	NULL
nucleus	NULL
for	NULL
at	NULL
least	NULL
90	NULL
min	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Since	NULL
DTCs	NULL
are	NULL
able	NULL
to	NULL
activate	NULL
JNK	NULL
(	NULL
18	NULL
)	NULL
and	NULL
NFAT	NULL
kinases	NULL
have	NULL
been	NULL
proposed	NULL
to	NULL
be	NULL
involved	NULL
and	NULL
implicated	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
export	NULL
of	NULL
NFAT-4	NULL
and	NULL
NFATe	NULL
,	NULL
respectively	NULL
(	NULL
5	NULL
,	NULL
61	NULL
)	NULL
,	NULL
we	NULL
next	NULL
analyzed	NULL
whether	NULL
NFATp	NULL
was	NULL
a	NULL
target	NULL
for	NULL
JNK	NULL
.	NULL

Solid-phase	NULL
kinase	NULL
analysis	NULL
of	NULL
JNK	NULL
immunoprecipitated	NULL
from	NULL
PBLs	NULL
treated	NULL
with	NULL
either	NULL
PMA	NULL
plus	NULL
ionophore	NULL
or	NULL
PDTC	NULL
indicated	NULL
that	NULL
both	NULL
stimuli	NULL
activated	NULL
JNK	NULL
activity	NULL
,	NULL
inducing	NULL
the	NULL
phosphorylation	NULL
of	NULL
both	NULL
NFATp	NULL
and	NULL
c-Jun	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

This	NULL
striking	NULL
result	NULL
shows	NULL
that	NULL
NFATp	NULL
is	NULL
a	NULL
substrate	NULL
of	NULL
JNK	NULL
,	NULL
which	NULL
is	NULL
activated	NULL
after	NULL
PBL	NULL
treatment	NULL
with	NULL
PDTC	NULL
or	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
composition	NULL
of	NULL
NFAT	NULL
changes	NULL
during	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
.	NULL

Thus	NULL
,	NULL
NFATp	NULL
is	NULL
rapidly	NULL
activated	NULL
and	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
within	NULL
minutes	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Several	NULL
hours	NULL
after	NULL
activation	NULL
,	NULL
the	NULL
bulk	NULL
of	NULL
NFATp	NULL
is	NULL
found	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
and	NULL
other	NULL
NFAT	NULL
family	NULL
members	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
mediate	NULL
NFAT	NULL
pendent	NULL
sustained	NULL
transcription	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
NFAT1/	NULL
p-deficient	NULL
mice	NULL
,	NULL
IL-2	NULL
gene	NULL
expression	NULL
upon	NULL
signaling	NULL
through	NULL
the	NULL
TCR	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
significantly	NULL
affected	NULL
(	NULL
22	NULL
,	NULL
72	NULL
)	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
other	NULL
NFAT	NULL
family	NULL
members	NULL
might	NULL
play	NULL
a	NULL
more	NULL
relevant	NULL
role	NULL
in	NULL
IL-2	NULL
gene	NULL
activation	NULL
or	NULL
compensate	NULL
for	NULL
the	NULL
absence	NULL
of	NULL
NFAT1/p	NULL
.	NULL

Since	NULL
we	NULL
had	NULL
observed	NULL
complete	NULL
inhibition	NULL
of	NULL
NFAT	NULL
-dependent	NULL
transcription	NULL
by	NULL
PDTC	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
analyze	NULL
by	NULL
EMSA	NULL
its	NULL
effects	NULL
on	NULL
the	NULL
kinetics	NULL
of	NULL
binding	NULL
of	NULL
NFAT	NULL
in	NULL
Jurkat	NULL
cells	NULL
activated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
.	NULL

These	NULL
experiments	NULL
showed	NULL
that	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
NFAT	NULL
probe	NULL
,	NULL
observed	NULL
after	NULL
1	NULL
h	NULL
of	NULL
activation	NULL
and	NULL
further	NULL
increased	NULL
after	NULL
4	NULL
and	NULL
8	NULL
h	NULL
,	NULL
was	NULL
inhibited	NULL
by	NULL
PDTC	NULL
at	NULL
all	NULL
different	NULL
times	NULL
analyzed	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
left	NULL
)	NULL
.	NULL

Serological	NULL
analysis	NULL
with	NULL
the	NULL
67.1	NULL
specific	NULL
anti-NFATp	NULL
antibody	NULL
revealed	NULL
the	NULL
predominant	NULL
presence	NULL
of	NULL
NFATp	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
cells	NULL
activated	NULL
for	NULL
1	NULL
h	NULL
,	NULL
while	NULL
8	NULL
h	NULL
after	NULL
activation	NULL
,	NULL
excess	NULL
of	NULL
the	NULL
specific	NULL
antiserum	NULL
only	NULL
blocked	NULL
and	NULL
supershifted	NULL
part	NULL
of	NULL
the	NULL
NFAT	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
right	NULL
)	NULL
.	NULL

Since	NULL
NFATe	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
transcriptionally	NULL
induced	NULL
during	NULL
T-cell	NULL
activation	NULL
(	NULL
43	NULL
)	NULL
and	NULL
is	NULL
detected	NULL
in	NULL
the	NULL
nucleus	NULL
later	NULL
after	NULL
T-cell	NULL
stimulation	NULL
(	NULL
29	NULL
)	NULL
,	NULL
we	NULL
performed	NULL
Northern	NULL
blot	NULL
analysis	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
expression	NULL
of	NULL
NFATe	NULL
during	NULL
activation	NULL
was	NULL
affected	NULL
by	NULL
PDTC	NULL
.	NULL

These	NULL
experiments	NULL
revealed	NULL
that	NULL
the	NULL
NFATe	NULL
mRNA	NULL
steady-state	NULL
levels	NULL
,	NULL
undetected	NULL
in	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
,	NULL
were	NULL
upregulated	NULL
after	NULL
1	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
,	NULL
peaked	NULL
at	NULL
4	NULL
h	NULL
,	NULL
and	NULL
were	NULL
maintained	NULL
at	NULL
high	NULL
levels	NULL
for	NULL
at	NULL
least	NULL
8	NULL
h	NULL
of	NULL
activation	NULL
.	NULL

Exposure	NULL
to	NULL
PDTC	NULL
prior	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
cells	NULL
drastically	NULL
inhibited	NULL
NFATc	NULL
gene	NULL
expression	NULL
at	NULL
the	NULL
times	NULL
analyzed	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
nuclear	NULL
export	NULL
of	NULL
NFATec	NULL
was	NULL
affected	NULL
by	NULL
PDTC	NULL
,	NULL
we	NULL
performed	NULL
immunofluorescence	NULL
analysis	NULL
of	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
HA-tagged	NULL
NFATe	NULL
(	NULL
1-418	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
DITHIOCARBAMATES	NULL
BLOCK	NULL
NFAT	NULL
ACTIVATION	NULL
-	NULL
6443	NULL
(	NULL
5x	NULL
GAL4	NULL
)	NULL
Luc	NULL
(	NULL
5XGAL4	NULL
)	NULL
Lue	NULL
GAL4-hNFAT1	NULL
(	NULL
1-415	NULL
)	NULL
GAL4-DBD	NULL
GAL4-c-JUNwt	NULL
GAL4-c-JUNSÂ¢S	NULL
,	NULL
``	NULL
(	NULL
A	NULL
250	NULL
-	NULL
re	NULL
p	NULL
1	NULL
&	NULL
>	NULL
B	NULL
L	NULL
9	NULL
ao	NULL
``	NULL
o	NULL
e	NULL
omi	NULL
Â§	NULL
A	NULL
o	NULL
to	NULL
150	NULL
-	NULL
B	NULL
'	NULL
3	NULL
=	NULL
)	NULL
30	NULL
B	NULL
A	NULL
3	NULL
&	NULL
A	NULL
100	NULL
-	NULL
20	NULL
a	NULL
e	NULL
E	NULL
50	NULL
-	NULL
10	NULL
o	NULL
-	NULL
0-4K	NULL
.	NULL

mem	NULL
.	NULL

CT-	NULL
_	NULL
[	NULL
G-29	NULL
a	NULL
0	NULL
N	NULL
@	NULL
R	NULL
&	NULL
V0	NULL
&	NULL
@	NULL
&	NULL
9	NULL
&	NULL
Â§	NULL
@	NULL
Â§	NULL
&	NULL
0	NULL
4	NULL
A	NULL
&	NULL
R	NULL
&	NULL
*	NULL
_	NULL
PDTC	NULL
PDTC/P+e	NULL
-	NULL
``	NULL
*	NULL
``	NULL
_	NULL
PDTC	NULL
PDTC/P+HIe	NULL
*	NULL
PDTC/PHe	NULL
-*	NULL
``	NULL
PDTC	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Opposite	NULL
effects	NULL
of	NULL
PDTC	NULL
on	NULL
the	NULL
transactivation	NULL
of	NULL
NFATp	NULL
and	NULL
c-Jun	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
cotransfected	NULL
by	NULL
lipofection	NULL
with	NULL
4	NULL
g	NULL
of	NULL
a	NULL
GAL4-Luc	NULL
reporter	NULL
plasmid	NULL
per	NULL
ml	NULL
together	NULL
with	NULL
2	NULL
jg	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
coding	NULL
for	NULL
the	NULL
fusion	NULL
proteins	NULL
GALA-hNFAT1	NULL
(	NULL
1-415	NULL
)	NULL
;	NULL
GAL4-c-Jun	NULL
(	NULL
wt	NULL
,	NULL
wild	NULL
type	NULL
)	NULL
;	NULL
the	NULL
mutated	NULL
version	NULL
,	NULL
GAL4-c-Jun	NULL
S	NULL
,	NULL
+	NULL
S	NULL
;	NULL
;	NULL
or	NULL
the	NULL
parental	NULL
empty	NULL
vector	NULL
RSV-GALA-DBD	NULL
per	NULL
ml	NULL
for	NULL
8	NULL
h.	NULL
After	NULL
36	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
25	NULL
or	NULL
50	NULL
uM	NULL
PDTC	NULL
and	NULL
further	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
wM	NULL
A23187	NULL
for	NULL
3	NULL
h.	NULL
The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
R.L.U	NULL
.	NULL
)	NULL

measured	NULL
for	NULL
30	NULL
s	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

These	NULL
experiments	NULL
revealed	NULL
that	NULL
the	NULL
translocation	NULL
of	NULL
recombinant	NULL
NFATc	NULL
to	NULL
the	NULL
nucleus	NULL
was	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
15	NULL
min	NULL
in	NULL
30	NULL
to	NULL
50	NULL
%	NULL
of	NULL
the	NULL
activated	NULL
cells	NULL
either	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
PDTC	NULL
.	NULL

However	NULL
,	NULL
after	NULL
90	NULL
min	NULL
,	NULL
the	NULL
nuclear	NULL
export	NULL
was	NULL
total	NULL
in	NULL
the	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
DTC	NULL
,	NULL
whereas	NULL
the	NULL
staining	NULL
pattern	NULL
remained	NULL
nuclear	NULL
in	NULL
90	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PDTC	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
combined	NULL
effects	NULL
of	NULL
PDTC	NULL
inhibiting	NULL
the	NULL
transactivating	NULL
functions	NULL
of	NULL
NFATp	NULL
and	NULL
the	NULL
transcriptional	NULL
induction	NULL
of	NULL
NFATc	NULL
might	NULL
well	NULL
account	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
binding	NULL
and	NULL
NFAT	NULL
reporter-dependent	NULL
transcription	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
given	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
NFAT	NULL
in	NULL
the	NULL
IL-2	NULL
gene	NULL
regulation	NULL
(	NULL
15	NULL
,	NULL
46	NULL
)	NULL
,	NULL
this	NULL
combined	NULL
effect	NULL
could	NULL
itself	NULL
account	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
and	NULL
expression	NULL
.	NULL

DISCUSSION	NULL
The	NULL
transmission	NULL
of	NULL
signals	NULL
derived	NULL
from	NULL
the	NULL
T-cell	NULL
stimulation	NULL
involves	NULL
at	NULL
least	NULL
three	NULL
different	NULL
pathways	NULL
mediated	NULL
by	NULL
Ras	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
and	NULL
Ca**-calcineurin	NULL
(	NULL
15	NULL
,	NULL
24	NULL
)	NULL
.	NULL

These	NULL
path	NULL
ways	NULL
couple	NULL
the	NULL
signals	NULL
from	NULL
the	NULL
plasma	NULL
membrane	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
which	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
genes	NULL
during	NULL
the	NULL
T-cell	NULL
activation	NULL
program	NULL
.	NULL

Among	NULL
these	NULL
genes	NULL
,	NULL
those	NULL
that	NULL
code	NULL
for	NULL
cytokines	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Cytokines	NULL
control	NULL
processes	NULL
such	NULL
as	NULL
proliferation	NULL
and	NULL
differ-entiation	NULL
,	NULL
as	NULL
well	NULL
as	NULL
multiple	NULL
effector	NULL
functions	NULL
of	NULL
immune	NULL
cells	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
CsA	NULL
and	NULL
FK	NULL
506	NULL
abrogate	NULL
the	NULL
cytokine	NULL
transcription	NULL
emphasizes	NULL
not	NULL
only	NULL
the	NULL
relevance	NULL
of	NULL
cytokines	NULL
in	NULL
regulating	NULL
the	NULL
immune	NULL
responses	NULL
,	NULL
but	NULL
also	NULL
the	NULL
central	NULL
role	NULL
that	NULL
the	NULL
Ca**-calcineurin	NULL
pathway	NULL
plays	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
different	NULL
DTCs	NULL
interfere	NULL
with	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
and	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
pyrrolidine	NULL
derivative	NULL
of	NULL
DTC	NULL
(	NULL
PDTC	NULL
)	NULL
on	NULL
the	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

This	NULL
analysis	NULL
revealed	NULL
that	NULL
PDTC	NULL
strongly	NULL
inhibited	NULL
NFAT	NULL
activation	NULL
by	NULL
mechanisms	NULL
different	NULL
from	NULL
those	NULL
used	NULL
by	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
CsA	NULL
and	NULL
FK	NULL
506	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
DTCs	NULL
block	NULL
IL-2	NULL
production	NULL
and	NULL
inhibit	NULL
the	NULL
surface	NULL
upregulation	NULL
of	NULL
T-cell	NULL
activation	NULL
antigens	NULL
such	NULL
as	NULL
CD69	NULL
and	NULL
CD25	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
B	NULL
.	NULL

&	NULL
9	NULL
3	NULL
al	NULL
B	NULL
o	NULL
s	NULL
&	NULL
9	NULL
=	NULL
*	NULL
n	NULL
Ac	NULL
Â»	NULL
5	NULL
15	NULL
30	NULL
90	NULL
5	NULL
15	NULL
30	NULL
90	NULL
min	NULL
s	NULL
b	NULL
#	NULL
4	NULL
|	NULL
rtorar	NULL
ha	NULL
<	NULL
cmuttv	NULL
cua	NULL
Â»	NULL
<	NULL
at	NULL
>	NULL
disc	NULL
}	NULL
--	NULL
+	NULL
Â»	NULL
f	NULL
NUCLEAR	NULL
sumy	NULL
._	NULL
...	NULL
enum	NULL
en	NULL
Cine	NULL
tot	NULL
4	NULL
%	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Shuttling	NULL
of	NULL
NFATp	NULL
in	NULL
PBLs	NULL
and	NULL
in	NULL
the	NULL
PEER	NULL
T-cell	NULL
line	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
fractionated	NULL
cell	NULL
extracts	NULL
from	NULL
PEER	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
or	NULL
PBLs	NULL
(	NULL
B	NULL
)	NULL
(	NULL
5	NULL
X	NULL
10Â°	NULL
cells	NULL
per	NULL
sample	NULL
in	NULL
total	NULL
and	NULL
10Â°	NULL
cells	NULL
for	NULL
nuclear	NULL
lysates	NULL
)	NULL
treated	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
with	NULL
1	NULL
M	NULL
ionophore	NULL
(	NULL
Io	NULL
)	NULL
either	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
100	NULL
wM	NULL
PDTC	NULL
for	NULL
2	NULL
h.	NULL
For	NULL
NFAT1/p	NULL
detection	NULL
,	NULL
the	NULL
antiserum	NULL
67.1	NULL
was	NULL
used	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
forms	NULL
of	NULL
NFATp	NULL
.	NULL

C	NULL
,	NULL
control	NULL
.	NULL

6444	NULL
MARTINEZ-MARTINEZ	NULL
ET	NULL
AL	NULL
.	NULL

P+Io	NULL
PDTC	NULL
-	NULL
0.25	NULL
4	NULL
0.25	NULL
0.5	NULL
1	NULL
4	NULL
h	NULL
C	NULL
--	NULL
m	NULL
Â»	NULL
emmm	NULL
)	NULL
-	NULL
c-Jun	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

JNK	NULL
phosphorylates	NULL
NFATp	NULL
in	NULL
vitro	NULL
.	NULL

PBLs	NULL
treated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
wM	NULL
ionophore	NULL
(	NULL
P+I0	NULL
)	NULL
or	NULL
100	NULL
wM	NULL
PDTC	NULL
were	NULL
lysed	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
antibody	NULL
specific	NULL
to	NULL
JNK1	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

The	NULL
immune	NULL
complexes	NULL
were	NULL
incubated	NULL
with	NULL
GST-c-Jun	NULL
(	NULL
1-79	NULL
)	NULL
or	NULL
GST-NFATp	NULL
(	NULL
1-415	NULL
)	NULL
in	NULL
kinase	NULL
buffer	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
y-	NULL
>	NULL
PJATP	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
stopped	NULL
and	NULL
separated	NULL
on	NULL
SDS-12	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Although	NULL
these	NULL
effects	NULL
clearly	NULL
reflect	NULL
inhibition	NULL
of	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
,	NULL
DTCs	NULL
by	NULL
themselves	NULL
also	NULL
trigger	NULL
signals	NULL
leading	NULL
to	NULL
a	NULL
moderate	NULL
surface	NULL
expression	NULL
of	NULL
CD69	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
CD69	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
or	NULL
in	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD3	NULL
MAb	NULL
was	NULL
not	NULL
completely	NULL
inhibited	NULL
by	NULL
DTCs	NULL
and	NULL
remained	NULL
at	NULL
the	NULL
same	NULL
level	NULL
as	NULL
those	NULL
induced	NULL
by	NULL
the	NULL
single	NULL
treatment	NULL
with	NULL
the	NULL
DTCs	NULL
.	NULL

This	NULL
activating	NULL
effect	NULL
resembles	NULL
that	NULL
exerted	NULL
by	NULL
PDTC	NULL
on	NULL
ICAM-1	NULL
activation	NULL
in	NULL
endothelial	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
and	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
transcriptional	NULL
induction	NULL
of	NULL
the	NULL
CD69	NULL
gene	NULL
promoter	NULL
through	NULL
AP-1	NULL
(	NULL
9a	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
fact	NULL
that	NULL
PDTC	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
a	NULL
sustained	NULL
and	NULL
strong	NULL
activation	NULL
of	NULL
JNK	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
as	NULL
well	NULL
as	NULL
in	NULL
human	NULL
PBLs	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
,	NULL
such	NULL
stimulation	NULL
may	NULL
also	NULL
be	NULL
related	NULL
to	NULL
the	NULL
observed	NULL
CD69	NULL
upregulation	NULL
.	NULL

Despite	NULL
its	NULL
ability	NULL
to	NULL
activate	NULL
AP-1	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
,	NULL
57	NULL
)	NULL
,	NULL
DTCs	NULL
have	NULL
been	NULL
proposed	NULL
as	NULL
potential	NULL
inhibitors	NULL
of	NULL
cytokine	NULL
production	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
virtue	NULL
of	NULL
their	NULL
capacity	NULL
to	NULL
block	NULL
NF-kB	NULL
activation	NULL
(	NULL
52	NULL
)	NULL
.	NULL

The	NULL
metal-che-lating	NULL
and	NULL
oxygen	NULL
radical-scavenging	NULL
antioxidative	NULL
properties	NULL
of	NULL
these	NULL
compounds	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
mediate	NULL
the	NULL
inhibition	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
as	NULL
occurs	NULL
with	NULL
DTCs	NULL
,	NULL
other	NULL
antioxidants	NULL
such	NULL
as	NULL
NAC	NULL
and	NULL
thioredoxin	NULL
not	NULL
only	NULL
are	NULL
inhibitors	NULL
of	NULL
NF-kB	NULL
,	NULL
but	NULL
also	NULL
activate	NULL
AP-1	NULL
(	NULL
38	NULL
,	NULL
51	NULL
,	NULL
52	NULL
,	NULL
63	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
the	NULL
antioxidants	NULL
NAC	NULL
and	NULL
BHA	NULL
also	NULL
interfere	NULL
with	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
,	NULL
their	NULL
inhibitory	NULL
effects	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
activation	NULL
antigens	NULL
and	NULL
IL-2	NULL
production	NULL
are	NULL
weaker	NULL
than	NULL
those	NULL
displayed	NULL
by	NULL
DTCs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
NAC	NULL
fails	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
nuclear	NULL
shuttling	NULL
of	NULL
NFATp	NULL
upon	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
NAC	NULL
on	NULL
T-cell	NULL
activation	NULL
might	NULL
be	NULL
more	NULL
related	NULL
to	NULL
its	NULL
capacity	NULL
to	NULL
inhibit	NULL
NF-kB	NULL
.	NULL

Although	NULL
these	NULL
experiments	NULL
suggest	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
DTCs	NULL
on	NULL
NFAT	NULL
are	NULL
not	NULL
related	NULL
to	NULL
their	NULL
reactive	NULL
oxygen	NULL
intermediate	NULL
scavenger	NULL
properties	NULL
,	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
stronger	NULL
antioxidative	NULL
potency	NULL
of	NULL
DTCs	NULL
could	NULL
account	NULL
for	NULL
such	NULL
effects	NULL
.	NULL

The	NULL
relative	NULL
contributions	NULL
of	NULL
different	NULL
members	NULL
of	NULL
the	NULL
NFAT	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
are	NULL
not	NULL
completely	NULL
understood	NULL
.	NULL

It	NULL
seems	NULL
that	NULL
NFAT	NULL
p	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
early	NULL
T-cell	NULL
activation	NULL
and	NULL
then	NULL
is	NULL
slowly	NULL
deactivated	NULL
(	NULL
29	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
bulk	NULL
of	NULL
NFATe	NULL
is	NULL
induced	NULL
and	NULL
activates	NULL
transcription	NULL
later	NULL
on	NULL
.	NULL

However	NULL
,	NULL
in	NULL
NFAT1/p-deficient	NULL
mice	NULL
,	NULL
IL-2	NULL
transcription	NULL
upon	NULL
signaling	NULL
through	NULL
the	NULL
TCR	NULL
is	NULL
not	NULL
significantly	NULL
affected	NULL
(	NULL
22	NULL
,	NULL
72	NULL
)	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
other	NULL
NFAT	NULL
family	NULL
members	NULL
may	NULL
play	NULL
a	NULL
more	NULL
important	NULL
role	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
PDTC	NULL
on	NULL
NFATe	NULL
may	NULL
be	NULL
more	NULL
relevant	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
than	NULL
that	NULL
exerted	NULL
on	NULL
the	NULL
transactivating	NULL
abilities	NULL
of	NULL
NFATp	NULL
.	NULL

The	NULL
prominent	NULL
role	NULL
of	NULL
NFATe	NULL
in	NULL
this	NULL
process	NULL
would	NULL
also	NULL
be	NULL
consistent	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL..	NULL
with	NULL
the	NULL
severe	NULL
inhibition	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
transdomi-nant	NULL
negative	NULL
of	NULL
NFATc	NULL
exerts	NULL
on	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
construct	NULL
(	NULL
reference	NULL
43	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
we	NULL
have	NULL
not	NULL
addressed	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
PDTC	NULL
blocks	NULL
NFATe	NULL
gene	NULL
expression	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
the	NULL
transcription	NULL
factors	NULL
inhibited	NULL
by	NULL
PDTC	NULL
would	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
NFATe	NULL
.	NULL

In	NULL
such	NULL
case	NULL
,	NULL
although	NULL
we	NULL
do	NULL
not	NULL
rule	NULL
out	NULL
that	NULL
DTCs	NULL
may	NULL
affect	NULL
other	NULL
transcription	NULL
factors	NULL
,	NULL
NF-	NULL
Â«	NULL
B	NULL
or	NULL
NFAT	NULL
family	NULL
members	NULL
would	NULL
be	NULL
good	NULL
candidates	NULL
for	NULL
regulation	NULL
of	NULL
NFATe	NULL
gene	NULL
transcription	NULL
.	NULL

Initially	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
normal	NULL
levels	NULL
of	NULL
NFATe	NULL
in	NULL
NFATp-deficient	NULL
mice	NULL
would	NULL
argue	NULL
against	NULL
an	NULL
essential	NULL
role	NULL
of	NULL
NFAT	NULL
p	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
NFATc	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
a	NULL
putative	NULL
role	NULL
of	NULL
NFATp	NULL
in	NULL
regulating	NULL
NFATc-inducible	NULL
expression	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
,	NULL
and	NULL
compensatory	NULL
mechanisms	NULL
may	NULL
also	NULL
operate	NULL
through	NULL
other	NULL
family	NULL
members	NULL
,	NULL
such	NULL
as	NULL
NFAT	NULL
'	NULL
x	NULL
,	NULL
in	NULL
the	NULL
deficient	NULL
mice	NULL
.	NULL

The	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
cis-acting	NULL
and	NULL
trans-acting	NULL
elements	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
NFATc	NULL
gene	NULL
promoter	NULL
will	NULL
clarify	NULL
which	NULL
factors	NULL
are	NULL
actually	NULL
involved	NULL
in	NULL
this	NULL
regula-tion	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
sustained	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
induced	NULL
by	NULL
ionophore	NULL
or	NULL
PMA	NULL
plus	NULL
ionophore	NULL
(	NULL
29	NULL
)	NULL
,	NULL
PDTC	NULL
triggered	NULL
a	NULL
rapid	NULL
nuclear	NULL
shuttling	NULL
of	NULL
NFATp	NULL
in	NULL
the	NULL
different	NULL
T-cell	NULL
types	NULL
analyzed	NULL
.	NULL

Recently	NULL
,	NULL
calcium	NULL
signaling	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
an	NULL
association	NULL
between	NULL
the	NULL
NFAT4	NULL
family	NULL
member	NULL
and	NULL
calcineurin	NULL
,	NULL
which	NULL
are	NULL
both	NULL
imported	NULL
to	NULL
the	NULL
nucleus	NULL
as	NULL
a	NULL
complex	NULL
.	NULL

Once	NULL
in	NULL
the	NULL
nucleus	NULL
,	NULL
a	NULL
putative	NULL
kinase	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
promote	NULL
the	NULL
nuclear	NULL
export	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
(	NULL
61	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
glycogen	NULL
synthase	NULL
kinase-3	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
phosphorylate	NULL
critical	NULL
serines	NULL
of	NULL
NFAT	NULL
that	NULL
are	NULL
required	NULL
for	NULL
nuclear	NULL
export	NULL
and	NULL
to	NULL
enhance	NULL
the	NULL
nuclear	NULL
exit	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
.	NULL

However	NULL
,	NULL
glycogen	NULL
synthase	NULL
kinase-3	NULL
activity	NULL
requires	NULL
the	NULL
previous	NULL
phosphorylation	NULL
of	NULL
NFATc	NULL
by	NULL
an	NULL
unknown	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
that	NULL
could	NULL
directly	NULL
phosphorylate	NULL
NFATe	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
about	NULL
the	NULL
existence	NULL
of	NULL
an	NULL
NFAT	NULL
kinase	NULL
activated	NULL
by	NULL
PDTC	NULL
that	NULL
would	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
accelerated	NULL
induction	NULL
of	NULL
the	NULL
nuclear	NULL
export	NULL
of	NULL
NFAT	NULL
.	NULL

Supporting	NULL
this	NULL
hypothesis	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
NFATp	NULL
exported	NULL
from	NULL
the	NULL
nucleus	NULL
of	NULL
PDTC-treated	NULL
cells	NULL
1h	NULL
4h	NULL
Sh	NULL
P+lo	NULL
Ih	NULL
-	NULL
P+lo	NULL
8h	NULL
6110	NULL
-	NULL
-	NULL
$	NULL
-	NULL
+	NULL
#	NULL
PDTC	NULL
P+lo	NULL
PDTC/P+Io	NULL
PDTC	NULL
P+lo	NULL
PDTC/P+Io	NULL
PDTC	NULL
P+lo	NULL
PDTC/P+Io	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Kinetics	NULL
analysis	NULL
and	NULL
contribution	NULL
of	NULL
NFATp	NULL
to	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
.	NULL

DNA-binding	NULL
activity	NULL
of	NULL
NFAT	NULL
was	NULL
analyzed	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
for	NULL
1	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
h	NULL
with	NULL
PDTC	NULL
or	NULL
PMA	NULL
plus	NULL
ionophore	NULL
(	NULL
P+I0	NULL
)	NULL
or	NULL
preincubated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
PDTC	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
ionophore	NULL
for	NULL
different	NULL
times	NULL
as	NULL
indicated	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

C	NULL
,	NULL
control	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
the	NULL
PMA	NULL
plus	NULL
ionophore	NULL
for	NULL
1	NULL
and	NULL
8	NULL
h	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
0.5	NULL
pl	NULL
of	NULL
the	NULL
anti-NFATp	NULL
antibody	NULL
67.1	NULL
.	NULL

The	NULL
autoradiograph	NULL
was	NULL
overexposed	NULL
to	NULL
visualize	NULL
the	NULL
supershifted	NULL
complex	NULL
,	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Doses	NULL
of	NULL
100	NULL
M	NULL
PDTC	NULL
,	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
1	NULL
M	NULL
A23187	NULL
were	NULL
used	NULL
in	NULL
single	NULL
or	NULL
combined	NULL
treatments	NULL
.	NULL

vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
A	NULL
1h	NULL
4h	NULL
T3	NULL
~~	NULL
g	NULL
n	NULL
n	NULL
Ba	NULL
Ba	NULL
2	NULL
g	NULL
2	NULL
&	NULL
e	NULL
R	NULL
A	NULL
T	NULL
A	NULL
a	NULL
T	NULL
a	NULL
JQ	NULL
-	NULL
AB	NULL
A	NULL
AB	NULL
Bie	NULL
=	NULL
Be	NULL
=	NULL
Be	NULL
$	NULL
#	NULL
#	NULL
A|	NULL
B-actin	NULL
unstimulated	NULL
DITHIOCARBAMATES	NULL
BLOCK	NULL
NFAT	NULL
ACTIVATION	NULL
-	NULL
6445	NULL
PMA+lIo	NULL
15	NULL
min	NULL
90	NULL
min	NULL
NFATc	NULL
.	NULL

.	NULL

.	NULL

.	NULL

-	NULL
=	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

Effect	NULL
of	NULL
PDTC	NULL
on	NULL
gene	NULL
expression	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
in	NULL
activated	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
mRNAs	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
50	NULL
uM	NULL
PDTC	NULL
(	NULL
PDTC	NULL
)	NULL
or	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
wM	NULL
A23187	NULL
(	NULL
P+I0	NULL
)	NULL
or	NULL
pretreated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
50	NULL
wM	NULL
PDTC	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
M	NULL
ionophore	NULL
(	NULL
PDTC/P+I0	NULL
)	NULL
for	NULL
1	NULL
and	NULL
4	NULL
h	NULL
were	NULL
isolated	NULL
,	NULL
separated	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
,	NULL
transferred	NULL
onto	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
,	NULL
and	NULL
sequentially	NULL
hybridized	NULL
with	NULL
NFATe	NULL
and	NULL
B-actin	NULL
cDNA	NULL
probes	NULL
.	NULL

C	NULL
,	NULL
control	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Staining	NULL
of	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
HA-tagged	NULL
NFATc	NULL
pretreated	NULL
or	NULL
not	NULL
with	NULL
50	NULL
wM	NULL
PDTC	NULL
for	NULL
2	NULL
h	NULL
and	NULL
further	NULL
stimulated	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
plus	NULL
1	NULL
M	NULL
ionophore	NULL
for	NULL
15	NULL
or	NULL
90	NULL
min	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
and	NULL
analyzed	NULL
by	NULL
immunofluorescence	NULL
with	NULL
anti-HA	NULL
antibody	NULL
.	NULL

The	NULL
subcellular	NULL
localization	NULL
of	NULL
HA-tagged	NULL
NFATc	NULL
in	NULL
resting	NULL
and	NULL
activated	NULL
cells	NULL
is	NULL
shown	NULL
in	NULL
the	NULL
upper	NULL
panels	NULL
,	NULL
and	NULL
that	NULL
of	NULL
PDTC-pretreated	NULL
cells	NULL
is	NULL
represented	NULL
in	NULL
the	NULL
lower	NULL
panels	NULL
.	NULL

displays	NULL
a	NULL
lower	NULL
mobility	NULL
than	NULL
that	NULL
of	NULL
untreated	NULL
cells	NULL
that	NULL
could	NULL
be	NULL
due	NULL
to	NULL
hyperphosphorylation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
.	NULL

Since	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
NFATp	NULL
is	NULL
directly	NULL
phosphorylated	NULL
by	NULL
JNK	NULL
and	NULL
that	NULL
PDTC	NULL
exerts	NULL
a	NULL
potent	NULL
and	NULL
sustained	NULL
activation	NULL
of	NULL
JNK	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
PBLs	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
sustained	NULL
activation	NULL
of	NULL
JNK	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
rapid	NULL
nuclear	NULL
exit	NULL
of	NULL
NFATp	NULL
.	NULL

However	NULL
,	NULL
in	NULL
vivo	NULL
experiments	NULL
will	NULL
be	NULL
required	NULL
to	NULL
elucidate	NULL
whether	NULL
JNK	NULL
is	NULL
indeed	NULL
involved	NULL
in	NULL
regulating	NULL
the	NULL
shuttling	NULL
of	NULL
NFATp	NULL
.	NULL

Alternatively	NULL
,	NULL
a	NULL
possible	NULL
late	NULL
effect	NULL
of	NULL
PDTC	NULL
involving	NULL
inhibition	NULL
of	NULL
calcineurin	NULL
that	NULL
would	NULL
allow	NULL
normal	NULL
kinases	NULL
to	NULL
reverse	NULL
NFATp	NULL
dephosphorylation	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

Independently	NULL
of	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
PDTC	NULL
promotes	NULL
the	NULL
accelerated	NULL
export	NULL
of	NULL
NFATp	NULL
from	NULL
the	NULL
nucleus	NULL
of	NULL
activated	NULL
cells	NULL
,	NULL
this	NULL
rapid	NULL
export	NULL
may	NULL
well	NULL
account	NULL
for	NULL
its	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
transactivation	NULL
of	NULL
NFATp	NULL
,	NULL
and	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
cellular	NULL
targets	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
may	NULL
help	NULL
the	NULL
design	NULL
of	NULL
new	NULL
strategies	NULL
and	NULL
drugs	NULL
for	NULL
immunosuppressive	NULL
purposes	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
maintenance	NULL
of	NULL
NFAT	NULL
in	NULL
the	NULL
nucleus	NULL
as	NULL
a	NULL
result	NULL
of	NULL
a	NULL
sustained	NULL
increase	NULL
in	NULL
Ca	NULL
,	NULL
``	NULL
*	NULL
,	NULL
but	NULL
not	NULL
a	NULL
transient	NULL
increase	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
required	NULL
to	NULL
switch	NULL
on	NULL
IL-2	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
65	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
activation	NULL
both	NULL
NF-kB	NULL
and	NULL
NFAT	NULL
by	NULL
DTCs	NULL
suggests	NULL
a	NULL
potential	NULL
use	NULL
of	NULL
these	NULL
agents	NULL
as	NULL
immunosuppressive	NULL
drugs	NULL
.	NULL

NFAT	NULL
and	NULL
NF-kB	NULL
control	NULL
the	NULL
transcription	NULL
of	NULL
many	NULL
cytokine	NULL
genes	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
response	NULL
to	NULL
proinflammatory	NULL
stimuli	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
and	NULL
in	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
(	NULL
3	NULL
,	NULL
46	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
DTCs	NULL
are	NULL
not	NULL
restricted	NULL
to	NULL
transformed	NULL
T-cell	NULL
lines	NULL
;	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
PDTC	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
cell	NULL
proliferation	NULL
and	NULL
CD25	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
costimulation	NULL
with	NULL
anti-CD28	NULL
and	NULL
anti-CD2	NULL
MAbs	NULL
(	NULL
1	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
IL-2	NULL
secretion	NULL
induced	NULL
by	NULL
costimulation	NULL
with	NULL
antibodies	NULL
against	NULL
TCR-CD3	NULL
and	NULL
CD28	NULL
(	NULL
30	NULL
)	NULL
.	NULL

As	NULL
occurs	NULL
with	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
in	NULL
activated	NULL
PBLs	NULL
,	NULL
DTCs	NULL
inhibit	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
activation	NULL
antigens	NULL
and	NULL
binding	NULL
of	NULL
NFAT	NULL
and	NULL
NF-kB	NULL
to	NULL
their	NULL
cognate	NULL
sequences	NULL
in	NULL
EMSAs	NULL
.	NULL

Based	NULL
on	NULL
their	NULL
effects	NULL
in	NULL
vitro	NULL
,	NULL
it	NULL
will	NULL
be	NULL
very	NULL
important	NULL
to	NULL
analyze	NULL
the	NULL
potential	NULL
of	NULL
DTCs	NULL
as	NULL
immuno-	NULL
suppressive	NULL
drugs	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
DDTC	NULL
has	NULL
already	NULL
been	NULL
used	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
patients	NULL
,	NULL
and	NULL
beneficial	NULL
effects	NULL
of	NULL
the	NULL
drug	NULL
in	NULL
delaying	NULL
AIDS	NULL
symptoms	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
47	NULL
)	NULL
.	NULL

However	NULL
,	NULL
several	NULL
effects	NULL
of	NULL
DTCs	NULL
observed	NULL
in	NULL
vitro	NULL
must	NULL
be	NULL
taken	NULL
into	NULL
consideration	NULL
when	NULL
the	NULL
use	NULL
of	NULL
these	NULL
drugs	NULL
in	NULL
vivo	NULL
is	NULL
evaluated	NULL
.	NULL

First	NULL
of	NULL
all	NULL
,	NULL
DTCs	NULL
activate	NULL
AP-1	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

This	NULL
effect	NULL
has	NULL
been	NULL
involved	NULL
in	NULL
the	NULL
upregulation	NULL
of	NULL
ICAM-1	NULL
expression	NULL
in	NULL
endothelial	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
likely	NULL
to	NULL
mediate	NULL
CD69	NULL
membrane	NULL
expression	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
other	NULL
AP-1-dependent	NULL
genes	NULL
.	NULL

Although	NULL
the	NULL
overall	NULL
effect	NULL
of	NULL
DTCs	NULL
in	NULL
cells	NULL
analyzed	NULL
seems	NULL
to	NULL
be	NULL
inhibitory	NULL
,	NULL
AP-1-dependent	NULL
gene	NULL
activation	NULL
could	NULL
potentially	NULL
interfere	NULL
with	NULL
the	NULL
putative	NULL
anti-inflammatory	NULL
properties	NULL
of	NULL
these	NULL
com-pounds	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
overdosage	NULL
or	NULL
long-term	NULL
treatments	NULL
with	NULL
PDTC	NULL
can	NULL
desensitize	NULL
cells	NULL
to	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
the	NULL
drug	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
although	NULL
DTCs	NULL
have	NULL
been	NULL
found	NULL
to	NULL
prevent	NULL
apoptotic	NULL
cell	NULL
death	NULL
(	NULL
7	NULL
,	NULL
13	NULL
,	NULL
56	NULL
)	NULL
,	NULL
they	NULL
have	NULL
also	NULL
been	NULL
involved	NULL
in	NULL
triggering	NULL
of	NULL
apoptosis	NULL
(	NULL
42	NULL
,	NULL
71	NULL
)	NULL
.	NULL

Although	NULL
at	NULL
the	NULL
times	NULL
and	NULL
doses	NULL
analyzed	NULL
,	NULL
DTCs	NULL
do	NULL
not	NULL
affect	NULL
the	NULL
viability	NULL
of	NULL
Jurkat	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
longer	NULL
treatments	NULL
with	NULL
these	NULL
agents	NULL
result	NULL
in	NULL
loss	NULL
of	NULL
cell	NULL
viability	NULL
associated	NULL
with	NULL
a	NULL
clear	NULL
pattern	NULL
of	NULL
apoptosis	NULL
.	NULL

Since	NULL
a	NULL
role	NULL
for	NULL
NF-kB	NULL
activation	NULL
in	NULL
the	NULL
suppression	NULL
of	NULL
signals	NULL
leading	NULL
to	NULL
cell	NULL
death	NULL
has	NULL
been	NULL
suggested	NULL
(	NULL
4	NULL
,	NULL
6	NULL
,	NULL
68	NULL
,	NULL
69	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
some	NULL
genes	NULL
whose	NULL
expression	NULL
is	NULL
regulated	NULL
by	NULL
NF-kB	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
protective	NULL
mechanisms	NULL
against	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Hence	NULL
,	NULL
these	NULL
possible	NULL
effects	NULL
must	NULL
be	NULL
contemplated	NULL
in	NULL
cases	NULL
in	NULL
which	NULL
in	NULL
vivo	NULL
protocols	NULL
involving	NULL
long-term	NULL
treatments	NULL
with	NULL
DTCs	NULL
are	NULL
used	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
a	NULL
potential	NULL
benefit	NULL
of	NULL
DTCs	NULL
versus	NULL
other	NULL
immunosuppressive	NULL
drugs	NULL
is	NULL
related	NULL
to	NULL
DTC	NULL
's	NULL
ability	NULL
to	NULL
target	NULL
other	NULL
cells	NULL
apart	NULL
from	NULL
those	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Thus	NULL
,	NULL
whereas	NULL
CsA	NULL
and	NULL
FK	NULL
506	NULL
mediate	NULL
in	NULL
vivo	NULL
immunosuppression	NULL
preferentially	NULL
through	NULL
T	NULL
lymphocytes	NULL
,	NULL
PDTC	NULL
can	NULL
also	NULL
efficiently	NULL
block	NULL
cytokine	NULL
production	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
VCAM-1	NULL
and	NULL
E-selectin	NULL
expression	NULL
in	NULL
endothelial	NULL
cells	NULL
activated	NULL
by	NULL
proinflammatory	NULL
stimuli	NULL
(	NULL
36	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Since	NULL
VCAM-1	NULL
and	NULL
ELAM-1	NULL
are	NULL
adhesion	NULL
molecules	NULL
involved	NULL
in	NULL
leukocyte-endothelial	NULL
cell	NULL
interactions	NULL
required	NULL
for	NULL
the	NULL
recruitment	NULL
and	NULL
emigration	NULL
of	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
6446	NULL
MARTINEZ-MARTINEZ	NULL
ET	NULL
AL	NULL
.	NULL

to	NULL
inflamed	NULL
tissues	NULL
,	NULL
it	NULL
will	NULL
be	NULL
very	NULL
important	NULL
to	NULL
determine	NULL
whether	NULL
such	NULL
processes	NULL
are	NULL
affected	NULL
by	NULL
DTCs	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
DTCs	NULL
to	NULL
inhibit	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
both	NULL
NFAT	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
immunocompetent	NULL
cells	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
these	NULL
compounds	NULL
have	NULL
previously	NULL
been	NULL
used	NULL
as	NULL
pharmaceutical	NULL
drugs	NULL
support	NULL
their	NULL
potential	NULL
use	NULL
as	NULL
immunosuppressants	NULL
.	NULL

While	NULL
such	NULL
use	NULL
will	NULL
require	NULL
a	NULL
careful	NULL
and	NULL
thorough	NULL
analysis	NULL
by	NULL
evaluation	NULL
of	NULL
the	NULL
overall	NULL
effects	NULL
of	NULL
DTCs	NULL
in	NULL
vivo	NULL
,	NULL
DTCs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
useful	NULL
probes	NULL
for	NULL
studying	NULL
signaling	NULL
pathways	NULL
and	NULL
regulation	NULL
of	NULL
transcription	NULL
factors	NULL
implicated	NULL
in	NULL
the	NULL
T-cell	NULL
activation	NULL
process	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
are	NULL
very	NULL
grateful	NULL
to	NULL
P.	NULL
Angel	NULL
,	NULL
G.	NULL
Crabtree	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
R.	NULL
Perona	NULL
for	NULL
providing	NULL
us	NULL
with	NULL
critical	NULL
reagents	NULL
that	NULL
made	NULL
this	NULL
work	NULL
possible	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
A.	NULL
Lopez-Rivas	NULL
,	NULL
F.	NULL
R.	NULL
Gonzdlez-Amaro	NULL
,	NULL
M.	NULL
Lopez-Cabrera	NULL
,	NULL
V.	NULL
Calvo	NULL
,	NULL
and	NULL
C.	NULL
Lopez	NULL
Rodriguez	NULL
for	NULL
stimulating	NULL
discussions	NULL
and	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manu-script	NULL
;	NULL
Eva	NULL
Moreno	NULL
for	NULL
excellent	NULL
secretarial	NULL
assistance	NULL
;	NULL
David	NULL
Sancho	NULL
for	NULL
providing	NULL
us	NULL
with	NULL
purified	NULL
anti-CD3	NULL
MAbs	NULL
;	NULL
and	NULL
M.	NULL
Ortiz	NULL
de	NULL
Land	NULL
&	NULL
-zuri	NULL
for	NULL
helpful	NULL
suggestions	NULL
for	NULL
the	NULL
manuscript	NULL
and	NULL
continuous	NULL
support	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
Ministerio	NULL
de	NULL
Educacion	NULL
y	NULL
Ciencia	NULL
(	NULL
MEC	NULL
)	NULL
of	NULL
Spain	NULL
CICYT	NULL
S	NULL
$	NULL
SAF94.0817	NULL
and	NULL
PM96-0076	NULL
and	NULL
grant	NULL
AC046/96	NULL
from	NULL
Comunidad	NULL
Autonoma	NULL
de	NULL
Madrid	NULL
(	NULL
CAM	NULL
)	NULL
(	NULL
to	NULL
J.M.R	NULL
.	NULL
)	NULL

.	NULL

S.M.M	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Ministerio	NULL
de	NULL
Educacion	NULL
y	NULL
Ciencia	NULL
,	NULL
P.G.A	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Comunidad	NULL
Autonoma	NULL
de	NULL
Madrid	NULL
,	NULL
J.A	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Arthritis	NULL
Foundation	NULL
,	NULL
and	NULL
A.L.A	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
grant	NULL
AC046/96	NULL
from	NULL
the	NULL
Comunidad	NULL
Autonoma	NULL
de	NULL
Madrid	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

AlgartÃ©	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
LÃ©cine	NULL
,	NULL
R.	NULL
Costello	NULL
,	NULL
A.	NULL
Plet	NULL
,	NULL
D.	NULL
Olive	NULL
,	NULL
and	NULL
J.	NULL
Imbert	NULL
.	NULL

1995.	NULL
in	NULL
vivo	NULL
regulation	NULL
of	NULL
interleukin-2	NULL
receptor	NULL
a	NULL
gene	NULL
transcription	NULL
by	NULL
the	NULL
coordinated	NULL
binding	NULL
of	NULL
constitutive	NULL
and	NULL
inducible	NULL
factors	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:5060-5072	NULL
.	NULL

2	NULL
.	NULL

Aramburu	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Azzoni	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
B.	NULL
Perussia	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
NFATp	NULL
and	NULL
NFAT	NULL
,	NULL
in	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
:	NULL
regulation	NULL
upon	NULL
CD16	NULL
ligand	NULL
binding	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:801-810	NULL
.	NULL

3	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
T.	NULL
Henkel	NULL
.	NULL

1994	NULL
.	NULL

Function	NULL
and	NULL
activation	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12:141-179	NULL
.	NULL

4	NULL
.	NULL

Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1997	NULL
.	NULL

Apoptosis	NULL
:	NULL
activate	NULL
NF-B	NULL
or	NULL
dic	NULL
?	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

7:94-96	NULL
.	NULL

5	NULL
.	NULL

Beals	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
C.	NULL
M.	NULL
Sheridan	NULL
,	NULL
C.	NULL
W.	NULL
Turck	NULL
,	NULL
P.	NULL
Gardner	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1997	NULL
.	NULL

Nuclear	NULL
export	NULL
of	NULL
NF-ATc	NULL
enhanced	NULL
by	NULL
glycogen	NULL
synthase	NULL
kinase-3	NULL
.	NULL

Science	NULL
275:1930-1933	NULL
.	NULL

6	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1996	NULL
.	NULL

An	NULL
essential	NULL
role	NULL
for	NULL
NF-	NULL
Â«	NULL
B	NULL
in	NULL
preventing	NULL
TNF-	NULL
Â«	NULL
-induced	NULL
cell	NULL
death	NULL
.	NULL

Science	NULL
274:782-784	NULL
.	NULL

7	NULL
.	NULL

Bessho	NULL
,	NULL
R.	NULL
,	NULL
K.	NULL
Matsubara	NULL
,	NULL
M.	NULL
Kubota	NULL
,	NULL
K.	NULL
Kuwakado	NULL
,	NULL
H.	NULL
Hirota	NULL
,	NULL
Y.	NULL
Waka-zono	NULL
,	NULL
Y.	NULL
W.	NULL
Lin	NULL
,	NULL
A.	NULL
Okuda	NULL
,	NULL
M.	NULL
Kawai	NULL
,	NULL
R.	NULL
Nishikomori	NULL
,	NULL
and	NULL
T.	NULL
Heike	NULL
.	NULL

1994	NULL
.	NULL

Pyrrolidine	NULL
dithiocarbamate	NULL
,	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
(	NULL
NF-kappa	NULL
B	NULL
)	NULL
activation	NULL
,	NULL
prevents	NULL
apoptosis	NULL
in	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
HL-60	NULL
cells	NULL
and	NULL
thymocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

48:1883-1889	NULL
.	NULL

8	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
X.	NULL
Mao	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
K.	NULL
Kovary	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NFAT-1	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fra-1	NULL
and	NULL
JunB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1911-1919	NULL
.	NULL

9	NULL
.	NULL

Burns	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
A.	NULL
W.	NULL
Boyd	NULL
,	NULL
and	NULL
P.	NULL
B.	NULL
Beverly	NULL
.	NULL

1982	NULL
.	NULL

Two	NULL
monoclonal	NULL
anti-human	NULL
T	NULL
lymphocyte	NULL
antibodies	NULL
have	NULL
similar	NULL
biologic	NULL
effects	NULL
and	NULL
recognize	NULL
the	NULL
same	NULL
surface	NULL
antigen	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

129:1451-1457	NULL
.	NULL

9a.Castellanos	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
C.	NULL
Munoz	NULL
,	NULL
M.	NULL
C.	NULL
Montoya	NULL
,	NULL
E.	NULL
Lara-Pezzi	NULL
,	NULL
M.	NULL
Lopez-Cabrera	NULL
,	NULL
and	NULL
M.	NULL
O.	NULL
de	NULL
Landszuri	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

10	NULL
.	NULL

Chuypilo	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
D.	NULL
Schomberg	NULL
,	NULL
R.	NULL
Gerwig	NULL
,	NULL
A.	NULL
Heinfling	NULL
,	NULL
R.	NULL
Reeves	NULL
,	NULL
F.	NULL
Grummt	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1993	NULL
.	NULL

Multiple	NULL
closely-linked	NULL
NFAT/octamer	NULL
and	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
sites	NULL
are	NULL
part	NULL
of	NULL
the	NULL
interleukin-4	NULL
promoter	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21:5694-5704	NULL
.	NULL

11	NULL
.	NULL

Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
M.	NULL
F.	NULL
Shannon	NULL
,	NULL
A.	NULL
G.	NULL
Bert	NULL
,	NULL
G.	NULL
R.	NULL
Ryan	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Vadas	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor/interleukin	NULL
3	NULL
locus	NULL
is	NULL
regulated	NULL
by	NULL
an	NULL
inducible	NULL
cyclosporin	NULL
A-sensitive	NULL
enhancer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:2466-2470	NULL
.	NULL

12	NULL
.	NULL

Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
A.	NULL
G.	NULL
Bert	NULL
,	NULL
F.	NULL
Jenkins	NULL
,	NULL
G.	NULL
R.	NULL
Ryan	NULL
,	NULL
M.	NULL
F.	NULL
Shannon	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Vadas	NULL
.	NULL

1995	NULL
.	NULL

Human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
enhancer	NULL
function	NULL
is	NULL
associated	NULL
with	NULL
cooperative	NULL
interactions	NULL
between	NULL
AP-1	NULL
and	NULL
NFATp/c	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2071-2079	NULL
.	NULL

13	NULL
.	NULL

Cotter	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
R.	NULL
S.	NULL
Fernandes	NULL
,	NULL
S.	NULL
Verhaegen	NULL
,	NULL
and	NULL
J.	NULL
V.	NULL
McCarthy	NULL
.	NULL

1994	NULL
.	NULL

Cell	NULL
death	NULL
in	NULL
the	NULL
myeloid	NULL
lineage	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

142:93-112	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BroL..	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
1989	NULL
.	NULL

Contingent	NULL
genetic	NULL
regulatory	NULL
events	NULL
in	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Science	NULL
243:355-361	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Clipstone	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
nucleus	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:1045-1083	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
cyclosporin-sensitive	NULL
element	NULL
in	NULL
the	NULL
human	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
gene	NULL
promoter	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:1365-1379	NULL
.	NULL

Gomez	NULL
del	NULL
Arco	NULL
,	NULL
P.	NULL
,	NULL
S.	NULL
Martinez-Martinez	NULL
,	NULL
V.	NULL
Calyo	NULL
,	NULL
A.	NULL
L.	NULL
Armesilla	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Redondo	NULL
.	NULL

1996	NULL
.	NULL

JNK	NULL
(	NULL
c-Jun	NULL
NH-terminal	NULL
kinase	NULL
)	NULL
is	NULL
a	NULL
target	NULL
for	NULL
antioxidants	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:26335-26340	NULL
.	NULL

Hibi	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Lin	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
A.	NULL
Minden	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
oncoprotein-	NULL
and	NULL
UV-responsive	NULL
protein	NULL
kinase	NULL
that	NULL
binds	NULL
and	NULL
potenti-ated	NULL
the	NULL
c-Jun	NULL
activation	NULL
domain	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2135-2148	NULL
.	NULL

Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
X.	NULL
Li	NULL
,	NULL
U.	NULL
Francke	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1995	NULL
.	NULL

NFATc3	NULL
,	NULL
a	NULL
lymphoid-specific	NULL
NFATc	NULL
family	NULL
member	NULL
that	NULL
is	NULL
calcium-regulated	NULL
and	NULL
exhibits	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:19898-19907	NULL
.	NULL

Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1994	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFATp	NULL
in	NULL
a	NULL
neuronal	NULL
cell	NULL
line	NULL
and	NULL
in	NULL
the	NULL
murine	NULL
nervous	NULL
system	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:28181-28186	NULL
.	NULL

Hodge	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
A.	NULL
M.	NULL
Ranger	NULL
,	NULL
F.	NULL
C.	NULL
de	NULL
la	NULL
Brousse	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
M.	NULL
J.	NULL
Grusby	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1996	NULL
.	NULL

Hyperproliferation	NULL
and	NULL
dysregulation	NULL
of	NULL
IL-4	NULL
expression	NULL
in	NULL
NFATp-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
4:397-405	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
Y	NULL
.	NULL

Sun	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
and	NULL
X.	NULL
Xu	NULL
.	NULL

1995	NULL
.	NULL

Isolation	NULL
of	NULL
two	NULL
new	NULL
members	NULL
of	NULL
NF-AT	NULL
gene	NULL
family	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
NF-AT	NULL
proteins	NULL
.	NULL

Immunity	NULL
2:461-472	NULL
.	NULL

Izquierdo	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Reif	NULL
,	NULL
and	NULL
D.	NULL
Cantrell	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
p21	NULL
``	NULL
``	NULL
*	NULL
during	NULL
T-cell	NULL
activation	NULL
and	NULL
growth	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
16:159-164.	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
Z	NULL
.	NULL

Miner	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
T-cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
is	NULL
a	NULL
substrate	NULL
for	NULL
calcineurin	NULL
and	NULL
interacts	NULL
with	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
365:352-355	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Lob	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7:333-342	NULL
.	NULL

Lee	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
E.	NULL
S.	NULL
Masuda	NULL
,	NULL
N.	NULL
Arai	NULL
,	NULL
K.	NULL
Arai	NULL
,	NULL
and	NULL
T.	NULL
Yokota	NULL
.	NULL

1995	NULL
.	NULL

Definition	NULL
of	NULL
cis-regulatory	NULL
elements	NULL
of	NULL
the	NULL
mouse	NULL
IL-5	NULL
gene	NULL
promoter	NULL
:	NULL
involvement	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell-related	NULL
factors	NULL
in	NULL
interleukin-5	NULL
expression	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:17541-17550	NULL
.	NULL

Liu	NULL
,	NULL
J	NULL
.	NULL

1993	NULL
.	NULL

FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
:	NULL
molecular	NULL
probes	NULL
for	NULL
studying	NULL
intracellular	NULL
signal	NULL
transduction	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
14:290-295	NULL
.	NULL

Loh	NULL
,	NULL
C.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Carew	NULL
,	NULL
J.	NULL
Kim	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

T-cell	NULL
receptor	NULL
stimulation	NULL
elicits	NULL
an	NULL
carly	NULL
phase	NULL
of	NULL
activation	NULL
and	NULL
a	NULL
later	NULL
phase	NULL
of	NULL
deacti-vation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3945-3954	NULL
.	NULL

Los	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Schenk	NULL
,	NULL
K.	NULL
Hexel	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
,	NULL
W.	NULL
Drige	NULL
,	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
.	NULL

1995	NULL
.	NULL

IL-2	NULL
gene	NULL
expression	NULL
and	NULL
NF-kB	NULL
activation	NULL
through	NULL
CD28	NULL
requires	NULL
reactive	NULL
oxygen	NULL
production	NULL
by	NULL
5-lipoxygenase	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:3731-3740	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Carew	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Recombinant	NULL
NFAT1	NULL
(	NULL
NFATp	NULL
)	NULL
is	NULL
regulated	NULL
by	NULL
calcineurin	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
mediates	NULL
transcription	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3955-3966	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Mechanisms	NULL
of	NULL
transactivation	NULL
by	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

1	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:141-147	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
T.-Y	NULL
.	NULL

Shaw	NULL
,	NULL
A.	NULL
Raghavan	NULL
,	NULL
J.	NULL
Aramburu	NULL
,	NULL
F.	NULL
Garcia-Cozar	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Perrino	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Interaction	NULL
of	NULL
calcineurin	NULL
with	NULL
a	NULL
domain	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
that	NULL
controls	NULL
nuclear	NULL
import	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:8907-8912	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
H.	NULL
Tokumitsu	NULL
,	NULL
A.	NULL
Tsuboi	NULL
,	NULL
J.	NULL
Shlomai	NULL
,	NULL
P.	NULL
Hung	NULL
,	NULL
K.-L.	NULL
Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
promoter	NULL
cis-acting	NULL
element	NULL
CLEO	NULL
mediates	NULL
induction	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
is	NULL
recognized	NULL
by	NULL
factors	NULL
related	NULL
to	NULL
AP-1	NULL
and	NULL
NFAT	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:7399-7407	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Y.	NULL
Naito	NULL
,	NULL
H.	NULL
Tokumitsu	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
F.	NULL
Saito	NULL
,	NULL
C.	NULL
Hannum	NULL
,	NULL
K.-T.	NULL
Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1995	NULL
.	NULL

NFAT	NULL
,	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
family	NULL
that	NULL
is	NULL
expressed	NULL
predominantly	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2697-2706	NULL
.	NULL

Mauri	NULL
,	NULL
N.	NULL
,	NULL
M.	NULL
K.	NULL
Offerman	NULL
Â»	NULL
,	NULL
R.	NULL
Swerlick	NULL
,	NULL
C.	NULL
Kunsch	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
M.	NULL
Ahmad	NULL
,	NULL
R.	NULL
W.	NULL
Alexander	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Medford	NULL
.	NULL

1993	NULL
.	NULL

Vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
(	NULL
VCAM-1	NULL
)	NULL
gene	NULL
transcription	NULL
and	NULL
expression	NULL
are	NULL
regulated	NULL
through	NULL
an	NULL
antioxidant-sensitive	NULL
mechanism	NULL
in	NULL
human	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

92:1866-1874	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1993	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
cyclosporin-sensitive	NULL
T-cell	NULL
transcription	NULL
factor	NULL
NF-ATp	NULL
.	NULL

Science	NULL
262:750-754	NULL
.	NULL

Meyer	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
Schreck	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeverle	NULL
.	NULL

1993	NULL
.	NULL

H	NULL
,	NULL
O	NULL
;	NULL
and	NULL
antioxidants	NULL
have	NULL
opposite	NULL
effects	NULL
on	NULL
activation	NULL
of	NULL
NF-xB	NULL
and	NULL
AP-1	NULL
in	NULL
intact	NULL
cells	NULL
:	NULL
AP-1	NULL
as	NULL
secondary	NULL
antioxidant-responsive	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:2005-2015.	NULL
voL	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

Minden	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Lin	NULL
,	NULL
F.-X	NULL
.	NULL

Claret	NULL
,	NULL
A.	NULL
Abo	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Selective	NULL
activation	NULL
of	NULL
the	NULL
JNK	NULL
signaling	NULL
cascade	NULL
and	NULL
c-jun	NULL
transcriptional	NULL
activity	NULL
by	NULL
the	NULL
small	NULL
GTPases	NULL
Rac	NULL
and	NULL
Cdc42Hs	NULL
.	NULL

Cell	NULL
81:1147-1157	NULL
.	NULL

Munoz	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
C.	NULL
Castellanos	NULL
,	NULL
A.	NULL
Alfranca	NULL
,	NULL
A.	NULL
Vara	NULL
,	NULL
M.	NULL
A.	NULL
Esteban	NULL
,	NULL
J.	NULL
M.	NULL
Redondo	NULL
,	NULL
and	NULL
M.	NULL
O.	NULL
de	NULL
Landfzuri	NULL
.	NULL

1996	NULL
.	NULL

Transcriptional	NULL
up-regulation	NULL
of	NULL
intracellular	NULL
adhesion	NULL
molecule-1	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
by	NULL
the	NULL
antioxidant	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
activating	NULL
pro-tein-1	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:3587-3597	NULL
.	NULL

Munoz	NULL
,	NULL
C.	NULL
,	NULL
D.	NULL
Pascual-Salcedo	NULL
,	NULL
M.	NULL
C.	NULL
Castellanos	NULL
,	NULL
A.	NULL
Alfranca	NULL
,	NULL
J.	NULL
AragonÃ©s	NULL
,	NULL
A.	NULL
Vara	NULL
,	NULL
J.	NULL
M.	NULL
Redondo	NULL
,	NULL
and	NULL
M.	NULL
O.	NULL
de	NULL
LandSzuri	NULL
.	NULL

1996	NULL
.	NULL

Pyrrolidine	NULL
dithiocarbamate	NULL
inhibits	NULL
the	NULL
production	NULL
of	NULL
interleukin-6	NULL
,	NULL
interleukin-8	NULL
,	NULL
and	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
by	NULL
human	NULL
endothelial	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
inflammatory	NULL
mediators	NULL
:	NULL
modulation	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
activity	NULL
.	NULL

Blood	NULL
88:3482-3490	NULL
.	NULL

Nobel	NULL
,	NULL
C.	NULL
S.	NULL
I.	NULL
,	NULL
M.	NULL
Kimland	NULL
,	NULL
B.	NULL
Lind	NULL
,	NULL
S.	NULL
Orrenius	NULL
,	NULL
and	NULL
A.	NULL
F.	NULL
G.	NULL
Slater	NULL
.	NULL

1995	NULL
.	NULL

Dithiocarbamates	NULL
induce	NULL
apoptosis	NULL
in	NULL
thymocytes	NULL
by	NULL
raising	NULL
the	NULL
intracellular	NULL
level	NULL
of	NULL
redox-active	NULL
copper	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:26202-26208	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
Chen	NULL
,	NULL
L.	NULL
Timmerman	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1994	NULL
.	NULL

NF-AT	NULL
components	NULL
define	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
targeted	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
369:497-502	NULL
.	NULL

Priesch	NULL
]	NULL
,	NULL
E.	NULL
E.	NULL
,	NULL
V.	NULL
Gouilleux-Gruart	NULL
,	NULL
C.	NULL
Walker	NULL
,	NULL
N.	NULL
E.	NULL
Harrer	NULL
,	NULL
and	NULL
T.	NULL
Baum-ruker	NULL
,	NULL
1995	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell-like	NULL
transcription	NULL
factor	NULL
in	NULL
mast	NULL
cells	NULL
is	NULL
involved	NULL
in	NULL
IL-5	NULL
gene	NULL
regulation	NULL
after	NULL
IgE	NULL
plus	NULL
antigen	NULL
stimulation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:6112-6119	NULL
.	NULL

Radler-Pohl	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Sachsenmaier	NULL
,	NULL
S.	NULL
Gebel	NULL
,	NULL
H.-P.	NULL
Auer	NULL
,	NULL
J.	NULL
T.	NULL
Bruder	NULL
,	NULL
U.	NULL
Rapp	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1993	NULL
.	NULL

UV-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
involves	NULL
obligatory	NULL
extranuclear	NULL
steps	NULL
including	NULL
Raf-1	NULL
kinase	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:1005-1012	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

1994	NULL
.	NULL

NFATp	NULL
:	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
coordinated	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
15:274-281	NULL
.	NULL

Reisinger	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
P.	NULL
Kern	NULL
,	NULL
M.	NULL
Ernst	NULL
,	NULL
P.	NULL
Bock	NULL
,	NULL
H.	NULL
D.	NULL
Flad	NULL
,	NULL
M.	NULL
Dietrich	NULL
,	NULL
and	NULL
German	NULL
DTC	NULL
Study	NULL
Group	NULL
.	NULL

1990	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV	NULL
progression	NULL
by	NULL
dithio-carb	NULL
.	NULL

Lancet	NULL
335:679-682	NULL
.	NULL

Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1995	NULL
.	NULL

Coordinate	NULL
and	NULL
cooperative	NULL
roles	NULL
for	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
murine	NULL
IL-4	NULL
gene	NULL
.	NULL

Immunity	NULL
2473-483	NULL
.	NULL

Ruff	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
L.	NULL
Leach	NULL
.	NULL

1995	NULL
.	NULL

Direct	NULL
demonstration	NULL
of	NULL
NFATp	NULL
dephosphorylation	NULL
and	NULL
nuclear	NULL
localization	NULL
in	NULL
activated	NULL
HT-2	NULL
cells	NULL
using	NULL
a	NULL
specific	NULL
NFATp	NULL
polyclonal	NULL
antibody	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:22602-22607	NULL
.	NULL

Sanchez-Mateos	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
F.	NULL
Sinchez-Madrid	NULL
.	NULL

1991	NULL
.	NULL

Structure-function	NULL
relationship	NULL
and	NULL
immunochemical	NULL
mapping	NULL
of	NULL
external	NULL
and	NULL
intracellular	NULL
anti-genic	NULL
sites	NULL
on	NULL
the	NULL
lymphocyte	NULL
activation	NULL
inducer	NULL
molecule	NULL
,	NULL
AIM/CD69	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21:2317-2325	NULL
.	NULL

Schenk	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Klein	NULL
,	NULL
W.	NULL
Erdbriigger	NULL
,	NULL
W.	NULL
Drige	NULL
,	NULL
and	NULL
K.	NULL
Schulze-Osthoff	NULL
.	NULL

1994	NULL
.	NULL

Distinct	NULL
effects	NULL
of	NULL
thioredoxin	NULL
and	NULL
antioxidants	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
NF-	NULL
Â«	NULL
B	NULL
and	NULL
AP-1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:1672-1676	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rieber	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

Reactive	NULL
oxygen	NULL
intermediates	NULL
as	NULL
apparently	NULL
widely	NULL
used	NULL
messengers	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
transcription	NULL
factor	NULL
and	NULL
HIV-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:2247-2258	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
B.	NULL
Heier	NULL
,	NULL
D.	NULL
N.	NULL
Miinnel	NULL
,	NULL
W.	NULL
Drige	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1992	NULL
.	NULL

Dithiocarbamates	NULL
as	NULL
potent	NULL
inhibitors	NULL
of	NULL
nuclear	NULL
factor	NULL
kB	NULL
activation	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1181-1194	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.	NULL
M.	NULL
Muller	NULL
,	NULL
and	NULL
W.	NULL
Shaffner	NULL
.	NULL

1989	NULL
.	NULL

Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
``	NULL
mini-extracts	NULL
,	NULL
``	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:6419	NULL
.	NULL

Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
DITHIOCARBAMATES	NULL
BLOCK	NULL
NFAT	NULL
ACTIVATION	NULL
56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

6447	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
13:136-142	NULL
.	NULL

Schulze-Osthoff	NULL
,	NULL
K.	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
and	NULL
W.	NULL
Drige	NULL
.	NULL

1994	NULL
.	NULL

Divergent	NULL
signalling	NULL
via	NULL
APO-1/Fas	NULL
and	NULL
the	NULL
TNF	NULL
receptor	NULL
,	NULL
two	NULL
homologous	NULL
molecules	NULL
involved	NULL
in	NULL
physiological	NULL
cell	NULL
death	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:4587-4596	NULL
.	NULL

Schulze-Osthoff	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Los	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1995	NULL
.	NULL

Redox	NULL
signalling	NULL
by	NULL
transcription	NULL
factors	NULL
NF-kB	NULL
and	NULL
AP-1	NULL
in	NULL
lymphocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

50:735-741	NULL
.	NULL

Sen	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
and	NULL
L	NULL
Packer	NULL
.	NULL

1996	NULL
.	NULL

Antioxidant	NULL
and	NULL
redox	NULL
regulation	NULL
of	NULL
gene	NULL
transcription	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

10:709-720	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Shaw	NULL
,	NULL
K	NULL
.	NULL

T.-Y	NULL
.	NULL

,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
A.	NULL
Raghavan	NULL
,	NULL
J.	NULL
Kim	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
J	NULL
.	NULL

Park	NULL
,	NULL
S.	NULL
Sharma	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1995	NULL
.	NULL

Immunosuppressive	NULL
drugs	NULL
prevent	NULL
a	NULL
rapid	NULL
dephosphorylation	NULL
of	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
in	NULL
stimulated	NULL
immune	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:11205-11209	NULL
.	NULL

Shibasaki	NULL
,	NULL
F.	NULL
,	NULL
E.	NULL
R.	NULL
Price	NULL
,	NULL
D.	NULL
Milan	NULL
,	NULL
and	NULL
F.	NULL
McKeon	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
kinases	NULL
and	NULL
the	NULL
phosphatase	NULL
calcineurin	NULL
in	NULL
the	NULL
nuclear	NULL
shuttling	NULL
of	NULL
transcription	NULL
factor	NULL
NF-AT4	NULL
.	NULL

Nature	NULL
382:370-373	NULL
.	NULL

Spits	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
Yssel	NULL
,	NULL
J.	NULL
Leeuwenberg	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
De	NULL
Vries	NULL
.	NULL

1985	NULL
.	NULL

Antigen-specific	NULL
cytotoxic	NULL
T	NULL
cell	NULL
and	NULL
antigen-specific	NULL
proliferation	NULL
T	NULL
cell	NULL
clones	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
cytolytic	NULL
activity	NULL
by	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
T3	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

15:88-91	NULL
.	NULL

Staal	NULL
,	NULL
F.	NULL
J.	NULL
T.	NULL
,	NULL
M.	NULL
Roederer	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
,	NULL
1990	NULL
.	NULL

Intracellular	NULL
thiols	NULL
regulate	NULL
activation	NULL
of	NULL
nuclear	NULL
factor	NULL
Â«	NULL
B	NULL
and	NULL
transcription	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:9943-9947	NULL
.	NULL

Szabo	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
J.	NULL
S.	NULL
Gold	NULL
,	NULL
T.	NULL
L.	NULL
Murphy	NULL
,	NULL
and	NULL
K.	NULL
M.	NULL
Murphy	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
controlling	NULL
interleukin-4	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
:	NULL
roles	NULL
for	NULL
NF-Y	NULL
and	NULL
NF-AT	NULL
,	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:4793-4805	NULL
.	NULL

Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
N.	NULL
A.	NULL
Clipstone	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
J.	NULL
P.	NULL
Northrop	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1996	NULL
.	NULL

Rapid	NULL
shuttling	NULL
of	NULL
NF-AT	NULL
in	NULL
discrimination	NULL
of	NULL
Ca**	NULL
signals	NULL
and	NULL
immunosuppression	NULL
.	NULL

Nature	NULL
383:837-840	NULL
.	NULL

Traenckner	NULL
,	NULL
E.B.-M.	NULL
,	NULL
H.	NULL
L.	NULL
Pahl	NULL
,	NULL
K.	NULL
N.	NULL
Schmidt	NULL
,	NULL
S.	NULL
Wilk	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1995	NULL
.	NULL

Phosphorylation	NULL
of	NULL
human	NULL
IxB-	NULL
Â«	NULL
on	NULL
serines	NULL
32	NULL
and	NULL
36	NULL
controls	NULL
pro-teolysis	NULL
IxB-	NULL
Â«	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
diverse	NULL
stimuli	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:2876-2883	NULL
.	NULL

Trunceh	NULL
,	NULL
A.	NULL
,	NULL
F.	NULL
Albert	NULL
,	NULL
P.	NULL
Golstein	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Schimitt-Verhulst	NULL
.	NULL

1985	NULL
.	NULL

Early	NULL
steps	NULL
of	NULL
lymphocyte	NULL
activation	NULL
by	NULL
synergy	NULL
between	NULL
calcium	NULL
ionophores	NULL
and	NULL
phorbol	NULL
ester	NULL
.	NULL

Nature	NULL
313:318-320	NULL
.	NULL

Van	NULL
Antwerp	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
S.	NULL
J.	NULL
Martin	NULL
,	NULL
T.	NULL
Kafri	NULL
,	NULL
D.	NULL
R.	NULL
Green	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1996	NULL
.	NULL

Suppression	NULL
of	NULL
TNF-	NULL
Â«	NULL
-induced	NULL
apoptosis	NULL
by	NULL
NF-	NULL
Â«	NULL
B	NULL
.	NULL

Science	NULL
274:787-789	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
M.	NULL
W.	NULL
Mayo	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1996	NULL
.	NULL

TNF-	NULL
and	NULL
cancer	NULL
therapy-induced	NULL
apoptosis	NULL
:	NULL
potentiation	NULL
by	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
.	NULL

Science	NULL
274:784-787	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Littman	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transduction	NULL
by	NULL
lymphocyte	NULL
antigen	NULL
receptors	NULL
.	NULL

Cell	NULL
76:263-274	NULL
.	NULL

Wu	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Lee	NULL
,	NULL
R.	NULL
E.	NULL
Bellas	NULL
,	NULL
S.	NULL
L.	NULL
Schauer	NULL
,	NULL
M.	NULL
Arsura	NULL
,	NULL
D.	NULL
Katz	NULL
,	NULL
M.	NULL
J.	NULL
FitzGerald	NULL
,	NULL
T.	NULL
L.	NULL
Rothstein	NULL
,	NULL
D.	NULL
H.	NULL
Sherr	NULL
,	NULL
and	NULL
G.	NULL
E.	NULL
Sonenshein	NULL
.	NULL

1996	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
Â«	NULL
B/Rel	NULL
induces	NULL
apoptosis	NULL
of	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:4682-4690	NULL
.	NULL

Xanthoudakis	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
P.	NULL
B.	NULL
Viola	NULL
,	NULL
K.	NULL
T.	NULL
Y.	NULL
Shaw	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
J.	NULL
D.	NULL
Wallace	NULL
,	NULL
P.	NULL
T.	NULL
Bozza	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

An	NULL
enhanced	NULL
immune	NULL
response	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
.	NULL

Science	NULL
272:892-895	NULL
.	NULL

Yano	NULL
,	NULL
O.	NULL
,	NULL
J.	NULL
Kanellopoulos	NULL
,	NULL
M.	NULL
Kieran	NULL
,	NULL
O	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
A.	NULL
IsraÃ©l	NULL
,	NULL
and	NULL
P.	NULL
Kouril-sky	NULL
.	NULL

1987	NULL
.	NULL

Purification	NULL
of	NULL
KBF1	NULL
,	NULL
a	NULL
common	NULL
factor	NULL
binding	NULL
to	NULL
both	NULL
H-2	NULL
and	NULL
beta	NULL
2-microglobulin	NULL
enhancers	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

63317-3324	NULL
.	NULL

